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The Role of Aryl Hydrocarbon Receptor (AHR) in Drug-Drug Interaction and the Expression of 
AHR in Pichia Pastoris  
 
 
Abstract 
 
 
by Yujuan Zheng 
 
University of the Pacific 
2018 
 
 
The aryl hydrocarbon receptor is a ligand-activated transcription factor that is involved in 
many important functions in the body.  To study the role and function of AHR, an abundant 
amount of in vitro expressed and purified protein is needed.  A baculovirus insect expression 
system is commonly employed to express AHR, however, there are several drawbacks with this 
method, such as mutation potential and high cost.   A better in overexpression system is needed 
and we hypothesize that Pichia pastoris, a yeast expression system, could stably express AHR 
and ARNT (aryl hydrocarbon receptor nuclear translocator) in sufficient amount with reasonable 
cost.  Codon optimized human AHR and ARNT genes were separately transformed into the 
Pichia pastoris genome and expressed.  Co-immunoprecipitation, gel-shift assay and western 
analysis indicate Pichia pastoris was able to stably overexpress functional AHR and ARNT 
proteins in comparable yield and lower cost compared to baculovirus insect expression system 
and the expressed proteins were used to develop a new in vitro method to study AHR and ARNT 
binding.  
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 Pharmacokinetic studies were performed to investigate the role of AHR in rutacarpine-
caffeine interactions.  Oral RUT pretreatment was shown to reduce oral caffeine area under the 
curve (AUC) in rats, due to an increase in caffeine clearance (CL) and a decrease in oral 
bioavailability (F).  RUT, an AHR ligand, increases caffeine CL by inducing Cyp1A2 enzyme, 
but the mechanism by which RUT reduces caffeine F is not understood.  We hypothesize that it 
is also mediated via AHR pathway.  To test the hypothesis, wild type (WT) and AHR knock out 
(KO) mice were administered caffeine IV and orally, with and without VEH or RUT 
pretreatment.  As expected, PK data show higher caffeine CL and lower F values in WT, but 
similar CL and F values in AHR KO mice, upon RUT co-administration.  
Rats study, in which with pretreatment of vehicle, AHR ligands: RUT, beta-
naphthoflavone or indole-3-carbinol before caffeine was dosed orally is consistent with mice 
study, that all three AHR agonists tested were able to reduce oral caffeine AUCs in rats.   
RUT reduces caffeine’s oral bioavailability is through AHR signaling pathway, however, 
the mechanism by which AHR mediates the reduced caffeine F is not known.   
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Chapter 1: Introduction 
1.1 Statement of Purpose  
Aryl hydrocarbon receptor (AHR) is a ubiquitous ligand-activated nuclear receptor that is 
known to be involved in many important functions in the human body and its role in cancer and 
the immune system makes it an interesting target to study as potential treatment options.  
Currently the exact mechanism of AHR’s signaling pathway is not fully delineated.  To study the 
role and function of AHR, an abundant amount of in vitro expressed and purified protein is 
needed.  A baculovirus insect expression system is commonly employed to express AHR; 
however, there are several drawbacks with this method, such as mutation potential, low yield and 
high cost.  A better in vitro expression system is needed and we hypothesize that Pichia pastoris, 
a yeast expression system, could stably express AHR and ARNT (aryl hydrocarbon receptor 
nuclear translocator) in abundant amount with reasonable cost.   
Rutaecarpine (RUT) is a pentacyclic indolopyridoquinazolinone alkaloid isolated from 
Evocardia rutaecarpa, an herb used in the traditional Chinese medicine for treatment of abdominal 
pain, dysentery and amenorrhea.  Ruta Cleanse and Ruta Sleep are natural supplements containing 
RUT, designed to speed up caffeine removal from blood.  Previous studies in the lab have shown 
that oral RUT pretreatment was able to reduce intravenous caffeine area under the curve (AUC) in 
rats due to an increase in clearance (CL) while a decrease in oral bioavailability in addition to an 
increase in CL are the causes for reduced caffeine AUC upon oral caffeine administration.  It is 
hypothesized that RUT, an AHR ligand, increases caffeine CL in rats by inducing Cyp1a2, a 
downstream gene in the AHR signaling pathway, but the mechanism by which AHR reduces 
caffeine oral bioavailability is not understood.  We hypothesize that it is also mediated via AHR 
pathway.   
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To summarize, the hypotheses for the project are: 
1. A Pichia pastoris expression system can be developed to stably overexpress functional 
AHR and ARNT proteins with comparable yield but lower cost compared to existing 
baculovirus insect expression system. 
2. The observed higher caffeine clearance and lower oral bioavailability upon RUT 
pretreatment in murine are both mediated via AHR signaling pathway. 
To test these hypotheses, there are six specific aims: 
1. Separately clone a stable codon-optimized human AHR and ARNT genes, with alcohol 
oxidase (AOX) promoter and 6-his tag at the end of AHR and ARNT genes, into Pichia 
pastoris genome to express human AHR and ARNT proteins. 
2. Purify and test the functionality of expressed AHR and ARNT proteins. 
3. Develop a limited proteolysis assay as a new in vitro method to study AHR and ARNT 
binding using Pichia pastoris expressed AHR and ARNT proteins. 
4. Conduct a caffeine pharmacokinetic study in rats with and without pretreatment with AHR 
ligands to determine if other AHR ligands, besides RUT, can also increase caffeine CL and 
reduce caffeine oral bioavailability. 
5. Conduct a caffeine pharmacokinetic study in rats with RUT pretreatment, in the presence 
and absence of an AHR antagonist, to determine if an AHR antagonist can abolish the 
observed increased in caffeine CL and reduced F values. 
6. Conduct caffeine pharmacokinetic study in wild type and AHR knock out mice with and 
without RUT pretreatment to determine if AHR is involved in the observed increased in 
caffeine CL and reduced F values. 
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Chapter 1 introduces the background of AHR, ARNT, AHR signaling pathway, AHR’s 
ligands and its downstream cytochrome P450 enzymes, and AHR’s involvement in drug-drug 
interactions.  
1.2 Aryl Hydrocarbon Receptor 
The aryl hydrocarbon receptor, which is ubiquitous in the human and mammalian bodies, 
is a ligand-activated nuclear receptor that can regulate numerous of genes.  It is well-known for 
mediating xenobiotic toxicity of carcinogens, so AHR is also called an environmentally sensitive 
transcription factor1.  AHR plays multiple roles in cellular homeostasis, proliferation, immune 
function2, T cell differentiation3, hematopoietic stem cell expansion4, glucose tolerance5, and the 
development of many human diseases6.  AHR is also involved in cancer cell’s initiation, 
promotion, progression, metastasis7, 8, and hematopoietic.  The mechanisms of AHR’s functions 
in the above mentioned processes are not clearly defined.   
1.3 AHR Signaling Pathway and Aryl Hydrocarbon Receptor Nuclear Translocator 
(ARNT) 
AHR is a member of the basic helix-loop-helix (HLH)-PER-AHR nuclear translocator 
(ARNT)-SIM (bHLH-PAS) family of nuclear transcriptional factors9.  As the only ligand 
activated member of bHLH-PAS family, without a ligand present, AHR exists in the cytoplasm 
in the silent state and is bound to its co-chaperones, which are known to be two molecules of 
Hsp90 (a 90 kDa molecular co-chaperone heat shock protein), and XAP2 (23iazinyl23cip-like 
protein X-Associated protein-2).  Hsp90 itself is bound to p23, an HSP90-interacting protein.  
The exact mechanism of AHR’s signaling pathway is not fully understood, however the current 
understanding is as follows (see Figure 1)10.  Once a ligand binds to AHR, AHR is activated and 
undergoes a conformational change, then the protein complex of AHR, hsp90, p23 and XAP2 
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will relocate into the nucleus where the complex will then dissociate.  After forming a 
heterodimer with ARNT protein in the nucleus, AHR can bind to xenobiotic response elements 
(XRE) or dioxin response element (DRE), which are located in the AHR responsive gene 
promoter regions, that regulate numerous downstream genes.  Then AHR will cycle back to the 
cytosol and be degraded1 (Figure 1).  
Many research reports indicate that a great variety of tumor types show not only higher 
levels of AHR expression than parent cell types, but also a significant constitutive receptor 
activity in both regular cancer and stem cancer cells.  Therefore, antagonists of AHR, which can 
block AHR’s protein function, have the potential for tumor treatment11 however, a recent 
research report stated that AHR inhibits lung cancer cell migration7, 12, 13.  AHR is expressed in 
most immune cells and its immune regulation also draws a lot of research attention2.  Because of 
these interesting findings of AHR’s role in cancer and immune system and AHR’s prevalence in 
the human body, even though the exact mechanism of AHR’s signaling pathway is not fully 
delineated, AHR draws abundant interest as a target for treatment of cancer and other diseases2, 6, 
7, 14.  It would be very informative and beneficial to get an abundant AHR, in order to elucidate 
AHR’s structure and do functional studies to provide more insights into cancer treatment and 
many other diseases.  The previous AHR protein expression method is the baculovirus insect 
expression system15 which needs infect the baculovirus into insect cells in each batch of protein 
expression, hence Ahr gene is not stably cloned into insect cells and the transfection process may 
introduce mutations after several generations of expression.  
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Figure 1:  The classic AHR pathway.  
 
 
1.4 AHR Ligands (TCDD, -NF, I3C) 
AHR which located in the cytoplasm and translocated into nucleus after activation, is a 
ligand-dependent transcription factor.  Its ligands include a broad range of compounds, 
endogenous as well as exogenous.  L-kynurenine 1 is an example of an endogenous AHR ligand. 
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD, a well-known potent AHR ligand), polycyclic 
aromatic hydrocarbons (PAHs, such as benzo(a)pyrene (BaP), 3-methylcholanthrene (3-MC), 
benzanthracenes and benzoflavones), and halogenated aromatic hydrocarbons (HAHs, such as 
biphenyls, polychlorinated dibenzodioxins, and dibenzofurans), are examples of exogenous AHR 
ligands.  Recently, research has focused on indole-3-carbinol (I3C), which is a plant nutrient and 
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another naturally occurring AHR ligand precusor16.  I3C is abundant in cruciferous plants and is 
reported to induce tumor cell death16.  
1.5 Phase I, II and III Enzymes  
Cytochromes P450 (CYP450) enzymes, which include a superfamily of heme-thiolate 
oxidoreductases, are named based on their spectral properties exhibiting a typical absorption 
maximum of the reduced carbon monoxide (CO)-bound complex at 450 nm17.   Cytochrome 
stands for hemoproteins, P for pigment and 450 for the absorption at 450 nm.  CYP450 enzymes 
are the major enzymes for oxidoreductive metabolism of both endogenous and exogenous 
compounds and play a critical role in drug metabolism, biosynthesis and degradation of 
endogenous compounds18.  They are often called Phase I drug metabolizing enzymes.  Through 
activation or heterolytic cleavage of oxygen molecules with insertion of one of its atoms into the 
substrate and reduction of the other to form water and with the presence of NADPH-CYP450 
reductase and phospholipids, CYP450 enzymes catalyze metabolic reactions18.  The ability of 
reduced CYP450 to generate an absorption peak at 450 nm upon CO binding is used for the 
estimation of the CYP450 content.  More than 5000 CYP450 genes have been cloned17, and 
some CYP450 enzymes have been fully characterized with crystal structures19.  CYP450 
members having more than 40% sequence identity are usually classified into the same gene 
family.  CYP450 enzymes could be induced, inhibited and/or saturated by their substrates or 
other compounds20.  This is one of the major reasons for drug-drug interactions (DDIs). 
The expression of many CYP450 enzymes are regulated by AHR.  Upon ligand binding, 
AHR can translocate into nucleus and start regulating downstream genes.  Cytochrome P450 
enzymes, which is one of the downstream gene families regulated by AHR, are phase I 
xenobiotic metabolizing enzymes, such as CYP1A and CYP1B families.  The expression of 
27 
 
CYP1A1 and CYP1B1, two of the enzymes in CYP450 family 1, are often used as AHR 
upregulating indicators. AHR regulates the transcription of CYP1A1 and CYP1B1 by binding to 
the nucleotide sequence NGCGTGN, which is also known as a dioxin response element (DRE).  
Out of 7 DREs which are located within 1600 base pairs (bp) upstream of the start codon of 
human CYP1A1, 4 DREs are functional21.  For CYP1B1, 2 out of 6 DREs in the human 
CYP1B1 upstream genes are functional22.  After AHR heterodimerizes with ARNT, AHR will 
bind to the DRE in the CYP1A1 or CYP1B1 promoter, triggering the activation of the expression 
of CYP1A1 or CYP1B1.  Except phase I enzymes, AHR can also regulate transporters, such as 
ABCG2, which will be discussed in the following.  
Phase II enzymes [such as NADPH dependent quinone oxidoreductase-1 (NQO1), 
UDPglucuronosyl transferase (UGT1A6)], and the transporters, which are called phase III 
proteins, such as multidrug resistance-associated proteins (MRPs), P-glycoprotein (P-gp), 
organic anion transporting polypeptide 2 (OATP2), and ABCG2,23 are reported to be AHR 
downstream genes as well.  Phase I and II drug metabolism enzymes and transporters play 
important roles in xenobiotic absorption, distribution, metabolism and excretion (ADME).  By 
regulating the expression of phase I, II and III proteins, AHR shows its effect on a compound’s 
ADME profile.  In mice, the same ligand at the same concentration could cause different levels 
of downstream gene expression in different organs8.  The same ligand treatment could also result 
in different downstream gene expression among different species 10, 24.  For instance, rats and 
mice treated with TCDD show only limited inter-species overlap in the responsive genes in the 
liver.  The same ligand treatment could also cause different expression level among different 
downstream genes.  For example, with 10 pM TCDD treatment, the mRNA levels of CYP1A1 is 
upregulated up to 100 fold in bovine primary cultured hepatocytes, however, no change in 
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CYP1B1 message level is detected 25.  Yet, it was reported that dioxin activates AHR more 
effectively for DRE in the CYP1B1 compared to CYP1A1 promoter regions in T47D human 
breast cancer cell line 26.  However, the precise mechanism is not clear.  
Transporters are also known as phase III enzymes.  Breast cancer resistance protein 
(BCRP) is one such transporter protein.  BCRP, with gene symbol as ABCG2, which was 
initially discovered in MCF-7, a breast cancer cell line 27, is a major ABC efflux transporter.  
BCRP is highly expressed in liver, placenta, small intestine and blood brain barrier 28, 29.  BCRP 
is an efflux transporter which pumps xenobiotics or toxic endogenous compound from fetal 
compartment to the maternal blood circulation in the placenta.  In the intestine, it is located in the 
apical side and it can pump compounds from epithelial cells to gut lumen, therefore its role in 
decreasing oral compound absorption 23.  
AHR has been reported to be involved in the regulation of BCRP efflux transporter in 
various cell lines such as human placental trophoblasts23, Caco 2 cell line 30, MCF7, human 
colon cancer cell line S1, 31 etc.  However, some researches indicate that AHR cannot regulate 
BCRP under TCDD treatment in hCMEC/D3 human cerebral microvascular endothelial cells 32. 
Recently, BCRP is reported to enhance yeast cells’ caffeine resistance 33.  This could be an 
evidence that BCRP can pump caffeine out of the cells.  
AHR’s regulation effect on Phase I-III enzymes can cause drug ADME change, hence 
AHR ligand could be the perpetrator for drug’s ADME change.  
1.6 Rutaecarpine 
Rutaecarpine (RUT) was reported as an AHR agonist that significantly induced CYP1A1 
mRNA and CYP1A1 protein levels through an AHR-dependent manner in both mice Hepa-
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1c1c734 and human HepG2 cell lines35.  Rutaecarpine induced Phase II enzyme  
glucuronytransferases (Ugt1a1 and Ugt1a6), Phase III enzyme hepatic uptake anion transporting 
peptides (Oatp1a1, Oatp1a4, Patp1b2, and Oatp2b1) and efflux transporter, multidrug resistance-
associated prteins (Mrp1, Mrp2, Mrp3, and Mrp4) with dose 20 mg/kg or higher in mice36.  
Rutaecarpine (8,13-dihydro-7H-indolo-[2’,3’:3,4]-pyrido-[2,1-b]-quinazolin-5-one) was 
originally extracted from unripe Evodia rutaecarpa fruit. Evodia rutaecarpa has been used in 
herbal medicine to treat headache, hypertension, gastrointestinal disorders, amenorrhea, anti-
inflammation, anti-thrombotic and anti-obesity for hundreds of years, in both China and Korea 
37-39.  Due to rutaecarpine’s many beneficial effects, it has been concomitantly used with other 
Chinese medicines; however, due to rutaecarpine’s induction of both cytochrome P450 enzymes 
and transporters, it causes herb-drug interactions36.  Furthermore, RUT is shown to slow down 
both gastric emptying and gastrointestinal transit in rats through stimulation of cholecystokinin 
(CCK) release and CCK1 receptor activation40.  CCK is a hormone that inhibits stomach 
emptying.  
RUT has complex effects on CYP450 enzymes, which are AHR regulated genes41.  It is 
reported that RUT affects CYP1A1, 1A2, 2B1, 2E1 and 3A enzymes activity in cell culture34, 
liver microsomes36 and in vito mice study34, 37, 39, 42.  Furthermore, it can induce CYP1A1 and 
1A2 mRNA and protein expression levels36; however, RUT is also reported to be a selective 
inhibitor of P450s in in vitro rat and human liver microsome studies41.  
There are several reports that show that RUT upregulates CYP1A1 in vitro, through AHR 
pathway34, 43 in mammalian cells, however, only  limited in vivo studies have shown a direct link 
between RUT and AHR pathway44.  
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1.7 Bioavailability 
Bioavailability (F) is defined as the fraction of an extravascularly administered dose of 
unchanged drug that reaches the systemic blood circulation.  There are many factors that can 
affect the rate and extent of oral drug absorption, such as a drug’s physicochemical properties 
(solubility, pKa, lipophilicity, particle size, diffusivity), drug formulation properties, anatomy 
and physiologic condition of gastrointestinal tracts, patient disease state, age, sex, diet, stress, 
BMI, concomitant drug administration, and intestinal and liver metabolizing enzymes and and 
transporters expression levels.  Any factor that can affect a drug’s dissolution, stability and 
intestinal permeability can also affect a drug’s bioavailability45.  
Mathematically, oral bioavailability equals the product of Fa*Fg*Fh (F= Fa*Fg*Fh), where 
Fa is the fraction of intact drug that is absorbed into intestinal cells, Fg is the fraction of intact 
drug that escapes gut wall metabolism, and Fh is the fraction of intact drug that escapes liver 
metabolism.  
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Chapter 2: Expression of Human AHR and ARNT Proteins in Pichia Pastoris and 
Functional Study of Expressed Proteins 
2.1 Statement of Problem 
To study the role and function of AHR, an abundant amount of in vitro expressed and 
purified protein is needed.  A baculovirus insect expression system is commonly employed to 
express AHR; however, there are several drawbacks with this method, such as mutation 
potential, low yield and high cost.  A better in vitro expression system is needed, and we 
hypothesize that a Pichia pastoris expression system can be developed to stably overexpress 
functional AHR and ARNT proteins with comparable yield and lower cost compared to existing 
baculovirus insect expression system.   
This chapter describes the methodology of using the Pichia pastoris protein expression 
system to express human AHR and ARNT proteins and the functional studies of Pichia 
expressed human AHR and ARNT proteins.  
2.2 Introduction 
 2.2.1 Pichia pastoris protein expression system.  Pichia pastoris has been commonly 
used to overexpress recombinant functional heterologous proteins due to its high yield, low cost, 
operational ease, and the fact that it is relatively less time consuming46, 47.  Pichia pastoris is a 
methylotrophic yeast which can use methanol as the only carbon source and trigger for protein 
expression.  Compared to another commonly used protein expression system, E. coli, which 
grow quickly, but cannot properly refold and provide proper posttranslational modification of 
mammalian proteins, Pichia provides eukaryotic post-translational modifications to proteins.  
Mammalian cell lines can express and assemble proteins with eukaryotic posttranslational 
modification; however, mammalian cell lines grow much slower and require more care, along 
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with more expensive media and more manipulations.  Moreover, humanized yeast glycosylation 
during posttranslational modification can generate more native protein products48.  The existing 
AHR and ARNT protein overexpression method is the baculovirus protein expression system.  In 
each batch of protein expression, it requires the transfection of insect Sf9 cells with baculovirus 
containing target gene of interest, and the chance of mutation in target genes increases with each 
passage of baculovirus.  However, in a Pichia protein expression system, a target gene is 
permanently cloned into the Pichia genome.  After the clone of interest is obtained, each batch of 
protein expression only requires the growth of Pichia cells containing target gene in an easily 
made media.  Overall, Pichia uses low cost media, requires minimal care, and can produce 
mammalian proteins with eukaryotic machinery.  Furthermore, yeast expressed proteins have 
been reported to be an applicable model system to study the p23 and AHR functions49-51.  
2.2.2 Codon optimization. Codon optimization, which is used in Pichia expressed 
human AHR and ARNT, is also called gene design and gene optimization, is the technology 
developed in recent years to optimize wild type gene sequences based on an expression host’s 
codon bias data to achieve the highest possible level of expression.  This technology not only 
considers the codon preference, but also takes into account a series of critical factors that affects 
protein expression such as A+T and C+G balance, cis-elements, TATA box and antivirus motifs 
in different hosts52, 53.  There are reports that prove that codon optimization can increase gene 
expression in message and protein expression levels in different types of host, like bacterial, 
yeast and mammalian cells54.  
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2.2.3 Hypothesis. We hypothesize that Pichia pastoris expression system can be 
developed to stably overexpress functional AHR and ARNT proteins with higher yield and lower 
cost compared to existing baculovirus insect expression system.   
2.2.4 Specific aims. To test the hypothesis, codon-optimized human AHR and ARNT 
genes, with alcohol oxidase (AOX) promoter and 6-his tag at the end of AHR and ARNT genes, 
will be cloned separately into the Pichia pastoris genome to express human AHR and ARNT 
proteins.  The expressed proteins will be purified using cobalt affinity purification columns and 
verified with Western blot and the functionality of expressed AHR and ARNT proteins will be 
tested with get-shift assays.  A limited proteolysis assay as a new in vitro method to study AHR 
and ARNT binding using Pichia pastoris expressed AHR and ARNT proteins will be developed. 
2.3 Material and Methodology  
2.3.1 Material. All chemicals and ingredients to prepare bacteria and yeast media (LB, 
YPD, BMGY, and BMMY) were purchased from Thermo Fisher Scientific (Hampton, NH) or 
Sigma Aldrich (St. Louis, MO).  All oligonucleotides, Dynabeads protein G, Zeocin, otherwise 
specified, were purchased from Thermo Fisher Scientific (Hampton, NH). −NF, L-kynurenine 
and thermolysin were purchased from Sigma Aldrich (St. Louis, MO).  All restriction enzymes 
were purchased from New England Biolabs (Ipswich, MA).  Anti-AHR SA210 rabbit IgG was 
purchased from Enzo Life Sciences (Farmingdale, NY).  Anti-ARNT H-172 rabbit IgG was 
purchased from Santa Cruz Biotechnology (Dallas, TX).  Anti-c-myc mouse IgG was purchased 
from Thermo Fisher Scientific (Grand Island, NY).  IRDye800 donkey secondary IgG was 
purchased from LI-COR (Lincoln, NE).  IRDye680-conjugated DRE was purchased from 
Integrated DNA Technologies (San Diego, CA).  The Gene Art codon optimized human AHR 
and ARNT sequences (GA-hAHR and GA-hARNT or PO-hARNT) were purchased from Life 
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Technologies (Thermo Fisher Scientific, Grand Island NY).  Cobalt agarose beads were 
purchased from Gold Biotechnology (St. Louis, MO).  The Gibson assembly kit was purchased 
from New England Bioabs (Ipswich, MA).  The Colony PCR master mix was purchased from 
Lucigen Corporation (Middleton WI).  The pPICZB plasmid and the Pichia strains (ySMD1163 
and yJC100) were gifts from Dr. Goeff Lin-Cereghino (University of the Pacific).  All other 
plasmids were generated by amplifying the corresponding cDNAs with the specific primers: 
human ARNT Pichia codon optimized cDNA was cloned into PmlI site of the pPICZB plasmid 
using primers OL766 and OL767. The colony PCR of huAHR-GA and huARNT-PO was 
conducted with primers OL599 and OL600 and OL768 and OL769, respectively (Table I).  
Western blot analyses were performed using a LI-COR Odyssey imaging system (Lincoln, NE).  
Electroporation was performed using an Eppendorf 2510 electroporator (Edison, NJ).  Cells 
pellets were homogenized using Bullet Blender Storm 24 (Troy, NY).  
Media and culture plates were made by following the recipes from “Pichia Expression 
Kit Version L” and are briefly introduced as below.  YPD (Yeast extract Peptone Dextrose) 
plate: 1% yeast extract, 2% peptone, 2% dextrose, 2% Agar. BMGY (Buffered Glycerol-
complex Medium): 1% yeast extract, 2% peptone, 10% 1 M potassium phosphate buffer at pH 
6.0, 1.34% YNB (Yeast Nitrogen Base), 4×10-5 % biotin, 1% glycerol.  BMMY is the same as 
BMGY except the replacement of 1% glycerol with 0.5% methanol.  
2.3.2 Cloning and expression of human AHR and ARNT genes in Pichia pastoris.  
The detailed protocol for cloning of human AHR by Pichia has been described previously51.  It is 
similar to the following protocol for cloning human ARNT gene into Pichia genome.   
  Our lab’s previous experiment with hAHR gene shows that non-codon optimized hAHR 
gene resulted in no expression of hAHR protein in Pichia (data not shown).  Therefore, codon 
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optimized full-length human ARNT cDNA was purchased from Life Technologies (Grand 
Island, NY).  This cDNA was cloned into PmlI site of pPICZB plasmid to generate pPICZB-PO-
hARNT plasmid by Gibson assembly with PCR product of Pml I overhang primer (Table 1) 
formed full-length hARNT cDNA.  The cloned plasmid was used to express human ARNT with 
c-myc and 6-His tags at the C-terminus. The pPICZB-PO-hARNT plasmid was propagated in 
BL21 cells to generate sufficient amount of linearized gene fragment containing hARNT gene 
(linearized with Invitrogen recommended Sac I enzyme, which only cuts at the plasmid sequence 
once but not the insert) before being transformed into the freshly prepared competent ySMD1163 
Pichia pastoris strain (a protease deficient Pichia strain) by electroporation using an Eppendorf 
2510 electroporator, according to the manufacturer’s recommendation (The preparation of  
 
 
 
Table 1: A list of oligonucleotides used in PCR Experiments. 
OL 599 Sense 5’ –ATG AAC TCC TCC TCC GCT AAC A -3’ 
OL600 Anti-Sense 5’- GAC CGG ATT CAG TAC ATT GGG AT- 3’ 
OL766 Sense 5’ TAA TTA TTC GAA ACG AGG AAT TCA CAT 
GGC TGC TAC TAC TGC TAA TCC AG 3’  
OL767 Anti-Sense 5’ GA TCC GAG ACG GCC GGC TGG GCC ACA CTC 
GGA GAA TGG TGG GAA CAT AGT 3’  
OL768 Sense 5’ CGA GGA ATT CAC ATG GCT GCT ACT A 3’ 
OL769 Anti-Sense 5’ ATG GCT TGT AAG AAC CGT CAG TGG 3’ 
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competent ySMD1163 cells could be found in “pPICZ A, B, and C Pichia expression vectors for  
selection on Zeocin and purification of recombinant proteins manual part no. 25-0148”).  To  
select for Pichia cells containing the codon-optimized hARNT gene stably integrated into the 
genome, the transformed Pichia cells were incubated in 1 mL of 1 M sorbitol at 30°C without 
shaking for 1 h, followed by the addition of 1 mL of YPD media. The resulting culture was then 
plated onto a YPD plate containing Zeocin (100 μg/mL), followed by 30°C incubation in a dark 
place for 2 – 4 days until the transformed yeast colonies were formed.  Colonies were then 
streaked to obtain individual colony and grown on another YPD plate containing Zeocin at 30 °C 
for 2-4 days.  The newly-formed colonies were validated by colony PCR to confirm the presence 
of the hARNT gene by using primers OL768 and OL769 (table 1).  For a 100 mL Pichia 
expressed hARNT purification, the freshly prepared colony was inoculated in BMGY media (50 
mL in a 250 mL baffled flask) and incubated at 29°C with rotation at 250 RPM until OD600 
reached 2-6 absorbance units.  A cell suspension equivalent to OD600 of 1 (100 mL/OD600, if 
OD600 = 4, 100 mL/OD600 = 25 mL) was centrifuged at 1,500 g for 5 min at room temperature.  
The resulting pellet was washed once with BMMY (50 mL) and then resuspended in 100 mL 
BMMY with 0.5% methanol in a 1 L baffled flask to induce the hARNT expression for 6 h with 
rotation at 250 rpm at 29°C.  The cell suspension was then centrifuged at 1,500 g for 5 min at 
4°C and the resulting cell pellet was washed with 20 mL of cold PBS. To harvest the hARNT 
protein, the cell pellet was lysed with ZROB05 beads (in equal volume as the pellet volume) in a 
5-fold volume of lysis buffer (25 mM HEPES, pH 7.4, 0.3 M KCl, 10% glycerol, 1 mM PMSF, 
and 2 μg/mL of leupeptin) using a Bullet Blender with the speed setting at 8 for 5 minutes at 4 
°C, followed by centrifugation at 14,000 g for 30 min at 4°C. The resulting supernatant, which 
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has the Pichia expressed hARNT protein, was collected as the starting material for metal-affinity 
purification using cobalt agarose beads.  
 2.3.3 Purification of Pichia expressed hAHR and hARNT proteins.  To purify AHR 
(GA-hAHR) and ARNT (GA-hARNT) proteins, after 1 mL of cobalt resin column was 
preconditioned by water and lysis buffer, Pichia cell lysate supernatant from 10 mL and 100 mL 
Pichia cell cultures of hAHR and hARNT, respectively, were poured onto the 1 mL cobalt resin 
column at 4°C.  The Pichia cell lysates were passed through the column 4 times.  The column 
was washed with 10 mL lysis buffer for both hAHR and hARNT purifications.  Another wash 
with lysis buffer containing 20 mM imidazole was applied onto hARNT’s purification.  To elute 
the protein that was bound to the resin, 5 mL of lysis buffer containing 500 mM imidazole was 
applied onto the column and the eluate was collected.  The majority of hAHR and hARNT 
proteins were captured in the first 1.5 mL of the eluates and went through dialysis to obtain 
Pichia pastoris hAHR and ARNT proteins in the final storage buffer (25 mM HEPES, pH 7.4, 1 
mM EDTA, 1 mM DTT, 50% glycerol, HEDG-50% buffer).  Coomassie Blue staining and 
Western blot analysis of 12% SDS-PAGE were used to determine the presence and purity of the 
purified proteins.  The purified hAHR and hARNT solution are called GA-hAHR and GA-
hARNT, respectively.  
2.3.4 Western blot analysis.  The general Western blot analysis using a near-infrared 
detection method was performed as described previously, with a slight modification5, 51.  Briefly, 
samples were mixed with SDS-PAGE electrophoresis sample treatment buffer, loaded and ran on 
a 12% SDS-PAGE gel to separate the proteins based on size.  Proteins on the gel were 
transferred to a nitrocellulose membrane at 120 V for 45 mins, followed by a blocking step 
incubation in a blocking buffer containing 5% BSA, 0.5% NaN3 and 0.1% Tween 20 at room 
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temperature for 1 h.  Subsequently the membranes were treated with primary and secondary 
antibodies.  Anti-AHR SA210 (1:5,000) and anti-ARNT H-172 (1:1,000) polyclonal antibodies 
were used as primary antibodies diluted in blocking buffer and incubated overnight at 4°C.  
Secondary antibody incubation (LI-COR IRDye 680 donkey anti-rabbit IgG, 1:10,000) was 
performed in the blocking buffer for 2 h at room temperature.  A LI-COR Odyssey imaging 
system was used for detection.   
2.3.5 Co-immunoprecipitation experiment.  GA-hAHR (4 μL) was incubated with 
either GA-hARNT (5 μL) or HEDG buffer (5μL) in HEDG-50% buffer, and BSA (100 μg) in 
HEDG buffer was added to the final volume of 200 μL and incubated at 30°C for 10 minutes.  
Anti-ARNT H-172 rabbit IgG (0.5 μg) was used to 38iazinyl38cipitated hARNT at room 
temperature for 30 min.  Prewashed Dynabeads protein G (5 μL) was then added to each sample 
followed by incubation for 4 h at 4°C with gentle rotation at 6 rpm.  After washing four times (5 
min each) with HEDG buffer containing 0.1% Tween-20, SDS-PAGE electrophoresis sample 
buffer was added to the beads.  Resulting eluted solutions in SDS-PAGE electrophoresis sample 
buffer were analyzed by Western blot analysis using anti-AHR antibody (SA210) to determine 
the amount of AHR co-immunoprecipitated with the addition of hARNT.  
2.3.6 Gel shift assay.  Pichia expressed hAHR (2 μL) and hARNT (0.2 μL) in HEDG-
50% buffer were incubated in 11 μL final volume of HEDG buffer at 30°C for 10 min in the 
presence or absence of a ligand (10 μM β-NF or 30 μM kynurenine) and 5 μg of proteins (Pichia 
ySMD1163 extract or BSA).  Pichia extract was the WT ySMD1163 cells lysate supernatant, 
which went through the same incubation and lysis processes as the transfected ySMD1163 in 
HEDG buffer.  Each sample was then added with poly-dIdC (1.5 μg) and KCl (with 110 mM 
final concentration).  The resulting solution was incubated at room temperature for 10 min, 
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followed by addition of IRDye680 conjugated DRE (250 fmol, 2 μL) and another 10 min 
incubation at room temperature.  Orange loading dye (2 μL) was added to each sample before 
samples were resolved on a 5% native 1 x TBE polyacrylamide gel at 4°C for 2 h at 185 V. After 
that, the gel was visualized with the LI-COR Odyssey image system.  
2.3.7 Limited Proteolysis by thermolysin. Proteolysis can be used for determining 
protein stability, which is an essential procedure for studying protein structures and protein-
protein interactions that result in global stability55, 56.  Limited proteolysis by thermolysin was 
used to study the interaction of Pichia expressed human AHR and ARNT.  Pichia expressed GA-
hAHR and GA-hARNT in HEDG-50% storage solution were dialyzed into proteolysis buffer (25 
mM HEPES, pH 7.4, 10% glycerol) to a concentration of 2 and 1 mg/mL, respectively.  1 μL of 
dialyzed hARNT was then added into 19 μL proteolysis buffer to a 20 μL final volume.  After a 
10-minute incubation at room temperature, samples were placed on ice for 5 min, followed by 
addition of 2 μL of 1 mg/mL themolysin stock solution.  Resulting solutions were incubated on 
ice for 1 min. Then proteolysis was stopped by the addition of 14 μL of 2 μL of 225 mM EDTA, 
and SDS-PAGE electrophoresis sample buffer was added to the solution to make the final 
concentration of 12.5 mM EDTA.  After vigorous mixing and heat treatment at 95°C for 2 min, 
samples were subjected analyzed by Western blot analysis.  
To study the effect of AHR on the limited proteolysis of ARNT protein by thermolysin, 1 
μL hARNT in proteolysis assay buffer was added to various amounts (1, 5, 10, or 15 μL) of 
dialyzed hAHR (2 mg/mL final total protein concentration) or Pichia extract (2 mg/mL WT 
Pichia lysate in proteolysis buffer) in the presence or absence of, 10 μM -NF, an AHR ligand.  
The resulting solutions were added to a corresponding volume of proteolysis buffer to a final 
volume of 20 μL.  Each sample was incubated at 30 °C room temperature for 10 min, followed 
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by incubation on ice for 5 min and then 2 μL of 1 μg/mL thermolysin was added.  The resulting 
samples were gently mixed by finger flicking and then incubated at 30°C for 10 minutes.  
2.3.8 Statistic analysis. GraphPad Prism 5 software was utilized for statistical analysis. 
Significant differences were determined by two tailed unpaired t-test to determine the statistical 
significance with 95% confidence intervals with * denoting p < 0.05, ** denoting p < 0.01, and 
ns denoting not statistically significant (p > 0.05).  The samples sizes were equal to 3, unless 
specified otherwise.  
2.4 Result  
 2.4.1 Characterization of recombinant human AHR expressed by Pichia pastoris.  
The Pichia expressed GA-hAHR protein was detectable by Western blot but not by Coomassie 
staining (Fig. 2).  Western blot analysis of metal affinity enriched hAHR showed that 5 μL 
(which is 0.6% of the total yield) of baculovirus AHR from a purification of ten T75 flasks of 
Sf9 cells had 2.5-fold higher amount AHR than 10 μL (which is 0.6% of the total yield) of GA-
hAHR from a 10 mL Pichia culture (Fig. 3). Thus, recombinant human AHR obtained from ten 
T75 flasks of Sf9 cells via baculovirus expression was close to the amount of human AHR 
generated from 25 mL (2.5 X 10 mL) of Pichia culture.  The culture of 25 mL Pichia culture was 
much easier than ten T75 flasks.  The amount of human AHR generated by 1 L of Pichia culture 
roughly translated into 40 μg AHR. When increased amount of Pichia cell lysate was loaded to 
the cobalt column, more hAHR was obtained in the first 1.5 mL eluate, but more AHR was lost 
into the flow through as well (data not shown).  Since the amount of hAHR that was enriched 
from a 10 mL Pichia culture cell lysate was relatively high and it was enough for subsequent 
functional studies, it was not necessary to waste hAHR in the flow through by loading higher 
volume of Pichia lysate.  A c-myc tag was present upstream to the 6-His tag in the Pichia 
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expressed AHR while the c-myc tag was absent in the baculovirus expressed AHR.  To 
investigate whether absence of c-myc tag would increase the expression yield of AHR, human 
AHR cDNA containing a C-terminal 6-His tag only (c-myc tag sequence was deleted) was 
cloned into the pPICZB plasmid and expressed in Pichia. 
Pichia containing AHR gene without c-myc tag was expected to produce equivalent or 
higher yield than Pichia AHR with c-myc tag.  Surprisingly, the presence of a c-myc tag 
upstream to the 6-His tag at the C-terminus increased the yield of human AHR production in 
Pichia (Fig. 4).   
 
 
 
 
Figure 2: Characterization of Human AHR Expression in Pichia by Western Blot Analysis and 
Coomassie Staining.  
Analysis of Pichia fractions from metal-affinity purification. Arrows indicate GA-hAHR. Left 
side is the image from Western blot, 5 μL samples were loaded per lane. Right side is the image 
from Commassie staining, 15 μL samples were loaded per lane.  
L, loading sample; FT, flow through sample; W, wash; E1-3, eluted fractions 1-3.  
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Figure 3: Yield comparison of human AHR expressed by Pichia and baculovirus systems.  
Comparison of the yield of Pichia- and baculovirus-derived affinity enriched human AHR. 5 μL 
of baculovirus AHR and 10 μL of GA-hAHR represents roughly 0.6% yield from ten T75 flasks 
of Sf9 cells and 10 mL of Pichia culture, respectively. 
 
 
 
 
 
Figure 4: Yield comparison of Pichia-AHR with or without the c-myc tag.  
Western blot analysis of Pichia expressed GA-hAHR with (+) or without (-) the c-myc tag. 
Crude Pichia lysate (5 μL) is the loading sample before affinity purification. Affinity enriched 
GA-hAHR (7.5 μL from 10 mL culture) from two separate expressions and purifications of 
Pichia expressed GA-hAHR ± c-myc tag.  
 
 
 
2.4.2 Characterization of recombinant human ARNT expressed by Pichia Pastoris. 
Pichia expressed human ARNT (Pichia-GA-hARNT) can be detected by both Western blot and 
Coomassie staining after it was affinity enriched (Fig. 5).  Western blot analysis of hARNT 
showed a strong band (~70 kDa) in E1 (Eluate 1), which was smaller than the full-length ARNT 
protein, indicating that it might be a truncated hARNT protein expressed in Pichia.  The Pichia-
hARNT protein was the major protein observed in Coomassie staining.  Since the Pichia lysates 
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of hAHR and hARNT was the same operation.  This indicated hARNT is expressed more 
abundantly than human AHR in Pichia expression system.  The majority of hARNT is in eluate 1 
(E1).  Eluate 2 (E2) also has hARNT; however, the amount in E2 is not detected by Coomassie 
staining.  The amount of hARNT in E2 (Eluate 2) is negligible since it can only be detected by 
Western blot and not by Coomassie stain.  The yield of the Pichia expressed human ARNT 
protein was compared to baculovirus method by Western blot analysis.  It showed that 1 μL of 
Pichia-GA-hARNT from a 200 mL of Pichia culture showed similar amounts as 1.5 μL of 
baculovirus ARNT from ten T75 flasks of Sf9 cells (Fig. 6).  This indicated that 130 mL of the 
Pichia culture should generate roughly the same amount of ARNT obtained from a routine 
baculovirus expression.  Since baculovirus system can express human ARNT protein in abundant 
amount15, it follows that human ARNT can be expressed abundantly by Pichia.  
2.4.3 Co-immunoprecipitation. After human AHR and ARNT proteins were expressed 
by Pichia, their functionality was tested.  First, since it is known that AHR and ARNT can form a 
heterodimer complex, their heterodimerization ability was investigated by co-
immunoprecipitation.  Western blot analysis showed that Pichia expressed human AHR could be 
co-immunoprecipitated only in the presence of Pichia-GA-hARNT (Fig. 7), indicating that 
Pichia expressed human AHR and ARNT were able to bind to each other and form the 
heterodimer in the absence of ligands, similar to previously observed binding in baculovirus 
expressed AHR and ARNT15.  This is also consistent with previous reports that Pichia expressed 
human AHR can interact with Hepa3B cell expressed human ARNT, allowing co-
immunoprecipitation of Pichia-GA-hAHR by anti-ARNT antibody51. 
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Figure 5: Western blot analysis of Pichia expressed human ARNT protein.  
5 μL per lane, analysis of fractions from metal-affinity purification of a 40 mL culture. L, 
loading sample; FT, sample after column flow through; W, wash; E1-3, eluted fractions 1-3. 
Arrows indicate GA-hARNT. 
 
 
 
 
Figure 6: Yield comparison of human ARNT expressed by Pichia and baculovirus systems.  
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Figure 7:  Co-immunoprecipitation result showing Pichia expressed human AHR and ARNT can 
bind to each other. αARNT indicates anti-ARNT antibody.  
 
 
 
2.4.4 Gel shift assay. It is known that the AHR-ARNT heterodimer can bind to DRE15 to 
regulate downstream genes in vivo. Gel shift assays can mimic this phenomenon, allowing the 
study of AHR and ARNT’s function in vitro.  Hence gel shift assays were performed to study 
whether Pichia AHR-ARNT complex could bind to DRE.  Results of the gel shift assay (Fig.8) 
showed that hAHR can form a gel shift complex of hAHR-hARNT-DRE in a ligand dependent 
manner (Fig.8 lanes 1-2, 7-8).  Both β-NF (10 mM stock solution) and kynurenine (30 mM stock 
solution) were used and both were able to cause the formation of the gel shift complex.  Pichia 
extract (prepared as described in the material section), which was the supernatant of WT Pichia 
whole cell lysate in the gel shift buffer, was necessary for GA-hAHR and GA-hARNT to form 
the gel shift complex (Fig. 8, Lanes 1, 5, 7, 9, 11).  This phenomenon is similar to the 
baculovirus expressed human AHR and ARNT proteins, which also requires exogenous protein 
factors from the expressed protein production host to form the gel shift complex15.   
2.4.5 Limited proteolysis. Results of limited proteolysis are shown in Figs. 9 and 10. 
Thermolysin remains active in the presence of urea, hence it can be used to distinguish between 
folded and unfolded protein conformations by subjecting proteins of interest to thermolysin 
digestion within a short time period in a urea-dependent manner.  The degree of thermolysin 
digestion will be different for different protein folding conformations since proteins unfold 
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differently in a urea gradient.  Fig.8a showed that BSA was stable after thermolysin treatment in 
the absence of urea.  Urea was used to unfold proteins to enable thermolysin to digest the 
proteins in the short incubation time by exposing thermolysin labile components; however, only 
BSA was stable against thermolysin treatment in the absence of urea.  Both GA-hAHR and GA-
hARNT were  
 
 
 
 
Figure 8: Gel Shift Assay Results showing Pichia-GA-hAHR and Pichia-GA-hARNT can form 
the ligand dependent AHR-ARNT-DRE complex.  
Upper arrow indicates GA-hAHR/GA-hARNT/DRE gel shift complex whereas the lower arrow 
indicates the free IRDye680-conjugated DRE. DRE sense, OL74, 
TCGAGTAGATCACGCAATGGGCCCAGC; DRE antisense, OL74, 
TCGAGCTGGGCCCATTGCGTGATCTAC, with DRE core sequence underlined.  
 
Completely degraded in 0.09 mg/mL thermolysin digestion with 1 minute incubation on ice (Fig. 
9a). Based on this data, whether binding of GA-hAHR to GA-ARNT could sterically interfere 
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and compete with thermolysin degradation of ARNT protein was investigated.  When 1,000-fold 
less thermolysin (0.09 μg/mL) was used, GA-hARNT was sufficiently detectable by Western 
blot analysis after digestion (Fig. 9b).  Adding up to 10-fold of GA-hAHR protected GA-hARNT 
from thermolysin degradation (Fig. 9b, lanes 1, 4, 5). This protective effect was GA-hARNT 
folding status dependent, since 90°C heat treatment for 15 min (lanes 3, 8, 9) or 70°C heat 
treatment for 1 h (lanes 2, 6, 7) effectively removed AHR’s protection.  This protection was 
AHR specific, not due to a general protein that exists in Pichia cells, since an equal amount of 
the protein content from the WT Pichia extract did not protect the ARNT degradation by 
thermolysin digestion (Fig. 10a).  This protection phenomenon remained in the presence and 
absence of β-NF (Figs. 10 a & b), therefore, this protective effect was ligand-independent.  The 
GA-hAHR-mediated protection was statistically significant (Fig. 10b), supporting the hypothesis 
that the interaction surface of AHR and ARNT contains the recognition site for ARNT 
degradation by thermolysin.  
 
 
 
 
 
 
48 
 
 
Figure 9: Thermolysin proteolysis showing protection of GA-hARNT degradation by GA-
hAHR. 
a), Western blot and Silver staining images showing the degradation of GA-hAHR, GA-hARNT, 
and BSA by thermolysin (0.09 mg/mL stock) in the absence of urea. B, anti-ARNT H-172 
Western blot image showing GA-hARNT degradation by thermolysin (0.09 μg/mL) in the 
absence of urea. GA-hARNT (70° C) and GA-hARNT (90° C) are samples heated at 70°C for 1 
h or 90°C for 15 min, respectively. 
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Figure 10: Thermolysin proteolysis showing protection of the GA-hARNT degradation by GA-
hAHR is independent of β-NF 
(a) anti-ARNT H-172 Western blot images showing GA-hARNT in the presence (+) or absence 
(−) of thermolysin (1 μg/mL stock) ± GA-hAHR (AHR) ± Pichia extract (PE) in the presence 
(top) or absence (bottom) of 10 μM β-NF. (b) Graph summarizes the experiment in (a) repeated 
with the n values indicated on the x-axis. 1-, 5-, 10-, and 15-fold refer to the protein amounts 
quantified by BCA assay with 1-fold equals the amount of the affinity enriched GA-hAHR 
added.  
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2.5 Discussion 
2.5.1 Expression of human AHR and ARNT in Pichia pastoris.  After the first human 
AHR and ARNT overexpression in a baculovirus system in 1990s15, baculovirus expressed 
human AHR and ARNT were continuously used for  human AHR binding study to its enhancer 
in Dr. William Chan’s lab at the University of the Pacific.  Around ten years later other labs 
applied the baculovirus system to express rat AHR to study its ligand binding57.  In the 
baculovirus expression system, in order for the insect cells to continually express recombinant 
proteins, it requires regular infection with cloned baculovirus to keep high titer viral stock.  This 
process of maintaining high titer viral stock could introduce mutations to the baculoviral genome 
over time, which might lower the yield or worse, alter the properties of the recombinant protein 
of interest.  On the contrary, the Pichia expression system requires less maintenance and more 
importantly, it is relatively reliable, since AHR and ARNT cDNA is integrated into the yeast 
genome. The transformed yeast cells, which can be made into glycerol stocks and stored at -
80°C, can be continuously used to produce the human AHR or ARNT proteins.  The initial 
attempt of expressing human AHR in Pichia pastoris generated no AHR expression when non-
codon optimized hAHR gene was cloned into Pichia genome.  Previous researchers in the lab 
made two changes to improve the expression yield: i) a protease-deficient strain of Pichia 
pastoris, ySMD1163, was used to increase the yield of target protein expression and ii) GeneArt 
human AHR (GA-hAHR) cDNA, which was codon optimized for Pichia protein expression, was 
cloned to allow Pichia to use its preferred codons and to minimized unstable mRNA sequences.  
The higher levels of GA-hAHR expression in ySMD1163 than wild type strain yJC100 (Figure 
11) were observed. This suggested that the protease-deficient yeast strain was beneficial for 
AHR production.  Furthermore, codon-optimization of human AHR cDNA sequence was 
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required for accumulation of AHR transcripts in Pichia pastoris. Interestingly, the c-myc tag 
located between the AHR and the 6-His tag at the C-terminus remarkably improved AHR protein 
expression (Fig. 4).  The presence and closeness of c-myc tag may provide some structural 
stability for AHR protein.  The amount of human AHR generated from Pichia and baculovirus 
expression were comparable.  For the baculovirus expression system, each batch of purification 
to obtain 750 μL affinity enriched human AHR required infection of ten 75 cm2 flasks of 
monolayer Sf9 cells for human AHR expression.  However, for Pichia pastoris, an equivalent 
amount of human AHR protein can be produced from only 25 mL of Pichia culture.  When a 
large scale of AHR is needed, it is easy to grow 200 mL or more Pichia cultures for protein 
expression at any given time.  Hence the economical and practical nature of Pichia system makes 
it a better alternative to obtain functional human AHR for mechanistic studies. Recently, Dr. 
William Chan’s group published their research work, where Pichia expressed human AHR and 
ARNT was used to facilitate its mechanistic study58.  For human ARNT protein expression, since 
it can already be expressed abundantly in the baculovirus system15, it was expected to be 
expressed in the similar level in the Pichia system.  However, codon optimization of human 
ARNT cDNA is also an essential prerequisite for successful expression of hARNT protein the 
Pichia expression system.  Both human AHR and ARNT protein expressions required codon 
optimization. Overall, considering the time and cost of cell culture plasticware and insect media 
(Table 2), expression of human ARNT proteins in Pichia is more time and cost effective than in 
the baculovirus system, leading it to be more attractive to obtain human ARNT protein from the 
Pichia expression system.  Currently, the structural information of full length human AHR is 
unknown due to the inability to obtain enough purified full length AHR for structural studies.  
Many researchers are investigating AHR’s structure using truncated AHR59, 60 and homologous 
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modeling coupled with mutagenesis data61, 62 to provide structural information for AHR.  We 
believe that it is straightforward and economical to scale up the production of full length AHR 
and ARNT in Pichia pastoris to obtain enough AHR and ARNT to perform AHR’s structural 
studies, once further refinements in the Pichia pastoris expression system are performed.   
2.5.2 Functional study of Pichia expressed AHR and ARNT.  Pichia expressed full length 
human AHR and ARNT proteins were shown to be functional.  They interacted with each other 
in a co-immunoprecipitation experiment and formed a ligand-dependent DRE complex in vitro.  
The formation of this AHR-ARNT-DRE gel shift complex required the addition of the yeast 
extract.  Even though the exact identity of the component from the yeast extract, critical for the 
formation of the complex is unknown.  It is consistent with existing observations that protein 
factors, such as the co-chaperone p2349, 57, 63 and the cyclophilin CyP4064, can promote the 
formation of this ternary complex.  This observation is consistent with the baculovirus expressed 
human AHR and ARNT15, suggesting that the addition of c-myc tag in Pichia expressed human 
AHR and ARNT  does not alter the properties of AHR and ARNT, since they behave similarly to 
baculovirus expressed human AHR and ARNT.  To study AHR’s protein conformation upon 
ligand or ARNT binding, a proteolysis assay was performed to investigate whether human AHR 
and ARNT were subjected to the urea-dependent degradation by thermolysin.  This protease 
cleaves proteins at hydrophobic amino acids (I, L, V, F, M,  
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Figure 11: Human AHR Expression comparison of yeast strain JC100 and SMD1163. P 
represents pellet extraction, L represents cell extract.  
 
 
Table 2: Comparison between Pichia and baculovirus protein expression methods 
 Pichia Baculovirus 
Functionality  Yes Yes 
Reproducibility for Long 
Term Protein Expression 
High Low 
Time Needed for each 
batch of protein expression  
 
2-3 days 2-3 week 
Cost Low High 
Yield High High 
Scale up Easy and Low cost Difficult and High Cost 
 
 
 
A) which usually exist in the hydrophobic core of a folded protein.  Hence applying themolysin 
in a urea gradient could reveal protein folding properties55, 65.  However, both Pichia expressed 
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human AHR and ARNT were degraded by themolysin in the absence of urea (Fig. 8a), 
suggesting that the hydrophobic residues of AHR and ARNT were exposed to the environment, 
not folded as expected.  This observation implies that AHR and ARNT proteins are relatively 
lipophilic, which may partly explain why bacterially 
expressed AHR and ARNT proteins are prone to form inclusion bodies.  This observation is 
consistent with the abundance of leucine and valine residues, which are potential cleavage sites 
of thermolysin in the PAS domain of AHR and ARNT, the water accessible interaction domains.  
Interestingly, AHR was successfully used for protecting ARNT from degradation by thermolysin 
suggesting that the interaction surface between AHR and ARNT is important for ARNT 
degradation by themolysin.  There is a great potential of developing a similar proteolysis assay 
using the Pichia expressed AHR and ARNT proteins to study the species-specific AHR/ARNT 
heterodimerization. 
2.6 Conclusion and Future Directions 
 
With codon-optimization and a protease deficient Pichia strain, Pichia pastoris could 
stably express AHR and ARNT in a sufficient amount with reasonable cost.  Purified AHR and 
ARNT proteins were able to form gel-shift complexes and were able to interact with each other 
in co-immunoprecipitation assays.  Limited proteolysis assay with thermolysin, using the 
purified AHR and ARNT, shows that AHR could protect ARNT from thermolysin degradation, 
which suggested that thermolysin cleaves ARNT in the AHR-ARNT interacting domain.  Pichia 
generated AHR and ARNT are new tools that can be used to study AHR signaling pathways and 
with further optimization, such as cloning multiple copies of AHR or ARNT genes into the 
Pichia genome or co-expression of AHR or ARNT with folding chaperone proteins, may further 
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improve the yield of expressed proteins.  The ultimate goal is to have an expression system that 
can generate an abundant amount of AHR in order to be able to generate a crystal structure for x-
ray crystallography.  Further modification of this Pichia method or other expression method is 
needed to gather more abundant and purer human AHR protein.   
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Chapter 3: Effect of AHR Agonists and Antagonist on Caffeine PK Profiles in Rats 
3.1 Statement of Purpose  
Coffee is one of the most widely consumed beverages in the world66.  Many people enjoy 
coffee, but they suffer the side effect as well.  Ruta Cleanse and Ruta Sleep are natural 
supplements containing rutaecarpine (RUT), designed to speed up caffeine removal from blood 
when needed.  RUT is isolated from Evocardia rutaecarpa, an herb used in traditional Chinese 
medicine. In 2015, our lab found that Sprague Dawley rats pretreated with RUT showed a 
decrease in caffeine systemic exposure upon oral caffeine administration.  The exposure decrease 
is not only due to an increase in its clearance, but also due to a decrease in caffeine oral 
bioavailability caused by a different factor than an increase in CL (which contributed slightly to 
a decrease in oral caffeine hepatic first pass bioavailability).  It is known that RUT induces 
caffeine’s metabolizing enzyme, Cyp1a2, which explains the increase in caffeine CL. This is 
expected since RUT is an AHR ligand.  However, the mechanism by which RUT reduces 
caffeine oral bioavailability is unknown, but we hypothesize that it is also mediated via the AHR 
pathway. 
To test this hypothesis, there are two specific aims: 
i. Conduct caffeine pharmacokinetic study in rats with and without pretreatment with  AHR 
ligands pretreatment to determine if other AHR ligands, besides RUT, can also increase 
caffeine CL and reduce caffeine oral bioavailability. 
ii. Conduct caffeine pharmacokinetic study in rats with RUT pretreatment, in the presence 
and absence of CH223191 (CH), an AHR antagonist, to determine if an AHR antagonist 
can abolish the observed increased in caffeine CL and reduced F values. 
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If AHR pathway is involved in the observed decrease in orally administered caffeine 
systemic exposure upon RUT pretreatment, rats pretreated with other AHR ligands, such as β-
NF and a precursor of AHR ligand, indole-3-carbinol (I3C), should show similar effect, these 
effects should be abolished upon co-treatment with an AHR antagonist, such as CH.  
The following introduces the background and exact experimental plan of this chapter.  
 
 
 
Figure 12: Structure of caffeine and its major metabolites: paraxanthine, theophylline and 
theobromine. 
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3.2 Introduction  
3.2.1 Caffeine. Caffeine (1, 3, 7- trimethylxanthine) is naturally occurring in coffee, tea 
and chocolate.  Caffeine is the most widely consumed psychoactive substance in the world, and 
is used as a cardiac, neurological and respiratory stimulant, diuretic, central nervous system 
stimulant, myocardial stimulant and smooth-muscle relaxant67, 68 as well. Caffeine is rapidly and 
almost completely absorbed (90%) when taken orally in human69, 70.  Its half-life is 3-7 hours in 
healthy adults, and it varies among people with different ages, health conditions, medications, 
diet and other conditions.  For instance, in smokers caffeine’s half-life was reduced up to 50% 
compared to nonsmokers69.  In contrast, in pregnant patients, its half-life will be prolonged up to 
15 hours due to low Cyp1A2 activity71. Caffeine has three major metabolites (Figure 12): 
paraxanthine (1, 7-dimethylxanthine) which accounts for 80% of caffeine’s metabolites in 
human, theobromine (3, 7-dimethylxanthine), and theophylline (1, 3-dimethylxatnhine)72.  In 
human and rats, caffeine’s major metabolizing enzymes are Cyp1A2 catalyzing N-
demethylation, and Cyp2E1 catalyzing N-1 and N-7 demethylations.  The percentage of three 
major metabolites varies among different species73.  Caffeine’s major metabolic enzyme is 
Cyp1A2. Cyp2E1, 3A4, 2C8 can also metabolize caffeine74. 
Caffeine exists in many beverages such as tea, energy drink, and coffee, which is the 
most widely consumed drink66, 68, 75.  It is reported that 85% of Americans intake caffeine daily 
with an average of 40 to 150 mg of caffeine.  An intake of 500 to 600 mg of caffeine per day, 
which is approximately 4 to 7 cups of coffee or 7 to 9 cups of tea, is regarded as a sign of health 
risk.  Due to its popularity, caffeinism, which refers to a state of acute or chronic toxicity as 
result of intake of high doses of caffeine, happens to one person in ten of the population76.  
Caffeine’s mild side effects are anxiety, restlessness, insomnia, fidgeting, elevated or irregular 
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heart rate, and increased urination.  In order to enjoy the benefits of coffee while being able to 
reduce its side effects quickly, Ruta Cleanse and Ruta Sleep, which are natural supplements 
containing RUT, were designed to speed up caffeine’s removal from the body due to RUT’s 
ability to induce caffeine’s metabolizing enzymes.    
3.2.2 Rutaecarpine and caffeine.  In 2005, RUT was shown to increase the metabolism 
of caffeine, and caffeine’s metabolite, theophylline67, for the first time. Later in 2011, RUT was 
reported to increase caffeine’s metabolism and urinary excretion via induction of Cyp1A2 and 
2E1 enzymes in rat38. RUT is commercially available as a natural supplement used for caffeine 
cleanser to reduce caffeine’s side effect. However, when RUT should be taken to achieve 
caffeine removal effect has not been studied. In 2015, our group studied the time dependent 
effect of RUT pretreatment on caffeine pharmacokinetics.  The data show that as early as 3 hours 
after 100 mg/kg RUT in suspension was administered orally to rats, Cyp1a2 activity, as shown 
by MROD assay, was increased 3-fold compare to VEH control group, and caffeine’s oral 
systemic exposure (area under the concentration vs. time curve) is significantly different than the 
control group.  An unexpected observation was that RUT can lower caffeine’s oral systemic 
exposure not only by increasing its clearance, but also by decreasing caffeine’s oral 
bioavailability.  The mechanism is independent of the increase in CL, since the magnitude of F 
decrease is significantly larger than the decrease in Fh value.  The oral caffeine AUC was 
decreased to 80% of control group after seven days of once daily 100 mg/kg oral RUT 
pretreatment.  To our knowledge, our PK study in 2015 were the first one conducted where 
caffeine was dosed intravenously and orally after RUT pretreatment so that the effect of RUT on 
caffeine oral bioavailability can be calculated.   
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3.2.3 Indol-3-Carbinol. Indole-3-carbinol (I3C, C9H9NO), a common phytochemical 
found in cruciferous vegetables, such as broccoli, brussel sprouts, and cauliflower, is a precursor 
of AHR ligand16, 43, 77, 78, 3,3-diindolylmethane (DIM) and indolo [3,2b] carbazole (ICZ)79.  I3C 
has shown to have many beneficial effects in animal and cell culture studies,  such as cytotoxic 
effect in colon and rectal cancer80, anti-inflammatory in the intestine16, and improving peanut 
allergy symptoms16.  I3C is reported to be a potent candidate as a chemotherapeutic compound16.   
Furthermore, I3C has been reported to increase AHR expression in MCF-7 cells81.  
3.3.4 CH223191. CH223191, 1-Methyl-N-[2-methyl-4-[2-(2-methylphenyl) 
60iazinyl]phenyl-1H-pyrazole-5-carboxamide 2-Methyl-2H-pyrazole-3-carboxylic acid (2-
methyl-4-o-tolylazo-phenyl)-amide is reported to be a pure and robust ligand specific AHR 
antagonist82.  CH223191 co-administration was shown to inhibit induction of Cyp1a1 mRNA, 
enzyme activity and protein expression in Hepa1c1c7 cells caused by 3-MC and RUT binding to 
AHR34.  In rats, the effective dose of CH223191 is 8 mg/kg/day83.  At that dose, CH was shown 
to normalize lung Cyp1a1 expression.  In mouse, the effective CH223191 dose is 10 mg/kg/day 
given in diet84.  CH caused reduced mRNA levels of Cyp1b1 and Scd1 in mice livers at this 
dose.  These data were available only recently, in 2017 and 2018 for mouse and rat studies, 
respectively.   
3.3 Hypothesis and Study Design  
 3.3.1 Specific hypothesis of AHR antagonist at study.  We hypothesize that the 
observed increase in caffeine CL and decrease in caffeine oral bioavailability upon RUT 
pretreatment in rats are mediated via AHR.  Therefore, concomitant administration of an AHR 
antagonist, such as CH223191, along with RUT, would abolish the observed increase in caffeine 
CL and decrease in caffeine oral bioavailability.  
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Figure 13: Structure of rutaecarpine (left) and β-nanphthoflavone (right).  
 
 
 
3.3.2 Study design of AHR antagonist rat study.  A cell culture study was conducted 
prior to rat pharmacokinetic study to test whether CH223191 can antagonize the effect of RUT.  
Hep3B cells will be separated into 6 groups,  RUT (1 μM), 3MC (1 μM), CH ( 0.5, 1, 2, or 10 
μM), RUT (1 μM) and CH ( 0.5, 1, 2, or 10 μM), 3MC (1 μM) and CH ( 0.5, 1, 2, or 10 μM), and 
DMSO group and pretreated for 24 hours.  After the 6 different pretreatments, cells were treated 
with 5 M methoxyresorufin and the formation of resorufin in the cell medium will be measured.    
Sprague-Dawley rats will be randomized and separated into 2 arms, one arm for IV 
caffeine while the other arm for oral caffeine dosing.  There are 4 groups (n = 4/group) in each 
arm, as shown in Table 3, for a total of 8 groups.  The four groups are vehicle (VEH, Cremophor 
EL: ethanol: H2O with 2:2:6), CH223191 (CH, 5 mg/kg), rutaecarpine (RUT, 100 mg/kg) or a 
cocktail of 100 mg/kg RUT and 5 mg/kg CH.  Rats will be daily pretreated orally with VEH, 
CH, RUT, or RUT + CH for 5 consecutive days before 15 mg/kg intravenous or 20 mg/kg orally 
caffeine dosing right after the 5th dose of pretreatment.  For consistency, the doses of caffeine 
(IV 15 mg/kg and PO 20 mg/kg) and RUT (PO 100 mg/kg) will be kept the same as our previous 
PK study in 2015.  Blood samples will be taken after caffeine dosing at 0.033, 0.0833, 0.25, 0.5, 
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1, 3, 5, and 8 hours.  Plasma will be obtained and stored at -80 °C prior to bioanalytical analysis.  
At the end of the study, rats will be sacrificed and tissues will be collected and frozen 
immediately prior to storage at -80°C.   
3.3.3 Specific hypothesis of AHR agonist rat study. We hypothesize that the observed 
increase in caffeine CL and decrease in caffeine oral bioavailability upon RUT pretreatment in 
rats are mediated via AHR.  Therefore, rats pretreated with other AHR agonists, such as β-NF 
and I3C, should also show a similar decrease in caffeine’s systemic oral exposure, as shown by 
RUT. 
3.3.4 Study design of AHR agonist study. The reported effective in vivo dose of oral β-
NF is 100-120 mg/kg in rats85, 86, therefore, we will use 120 mg/kg β-NF for our study.  The 
reported minimal effective dose of I3C in rats is 20 mg/kg87 and but the highest dose reported for 
mice is 5-6 mg/kg 16, therefore, based on highest dose in mice, which is equivalent to 167 mg/kg 
I3C in rats, was chosen for our study.   
Randomized Sprague-Dawley rats (n = 4) will be pretreated orally with vehicle (Veh, 
Cremophor EL: ethanol: H2O with 2: 2: 6), or with AHR ligands: 120 mg/kg -NF in VEH) or 
167 mg/kg I3C in VEH, for 5 days before 20 mg/kg caffeine is dosed orally. Blood samples will 
be taken after caffeine dosing at 0.033, 0.0833, 0.25, 0.5, 1, 3, 5, and 8 hours.  Plasma will be 
obtained and stored at -80oC prior to bioanalytical analysis.  At the end of the study, rats will be 
sacrificed, and tissues will be collected and freezed immediately prior to storage at -80oC.   
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Table 3: Expected result of caffeine PK study, with RUT pretreatment, with or without CH, in 
rats 
 
 
 
3.4 Material and Method 
3.4.1 Material and animal.  Ruteacarpine was donated by Linnet Biopharmaceuticals. 
CH223191 was purchased from Stemcell Technologies (Vancouver, Canada).  Caffeine (>99% 
purity), cremophor EL (polyethoxylated castor oil), resorufin (95%), β-nicotinamide adenine 
dinucleotide phosphate (β-NADPH), 3-methylcholanthrene (3-MC), corn oil, EMEM medium, 
antibiotic anti mycotic solution, and fetal bovine serum (FBS) were obtained from Sigma-
Aldrich (Switzerland).  Pierce™ BCA Protein Assay Kit was from Thermo Scientific. Kinetex 5 
μm C18 column (4.6 x 250 mm) was purchased from Phenomenex (Torrance, CA).  Tissue miser 
homogenizer was from Fisher Scientific, and Teflon glass hand homogenizer was obtained from 
Thomas Scientific.  96 well UV and fluorescence microplates and analytical grade methanol 
were obtained from Spectrum Chemicals (Gardena, CA). Tristar LB 941 microplate 
spectrophotometer was from Berthold Technologies (Oak Ridge, TN).  
Group Description Caffeine 
Dosing 
Size (n) Expected Changescompared to 
control 
CL F 
1 VEH control IV 4   
2 CH IV 4   
3 RUT IV 4    
4 RUT + CH IV 4   
5 VEH control PO 4   
6 CH PO 4   
7 RUT PO 4    
8 RUT + CH PO 4   
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Male Sprague-Dawley (SD) rats used in the AHR antagonist PK study were obtained 
(and PK study was performed) by Genentech Inc. (South San Francisco, CA).   Male SD rats 
used in the AHR agonist study were obtained (and PK study was performed) by Covance 
Laboratories (Princeton, NJ).   
3.4.2 Methoxyresofufin-O-deethylase (MROD) assay in culture study of CH223191.  
Hep3B cells were cultured in EMEM supplemented with 10% heat inactivated FBS, 100 U/mL 
penicillin, and 100 μg/mL streptomycin in an incubator (5% CO2, 37 °C).  Cells were grown to 
reach confluence in a 6-well plate before experiments.  Wells (n = 3/treatment) were incubated 
with or without RUT (1 μM), CH (0.5, 1, 2, or 10 μM), 3-MC (1 μM), cocktail of RUT (1 μM) 
and CH (0.5, 1, 2, or 10 μM) or cocktail of 3MC (1 μM) and CH (0.5, 1, 2, or 10 μM) in fresh 
media with 0.1% DMSO for 24 h, followed by washing with fresh media, and followed with 
incubation in fresh media for 30 min.  Then cells were incubated in fresh media containing 5 µM 
methoxyresorufin and 10 µM dicumarol for 1h before 200 µl media of each well were sampled 
and analyzed with a fluorimeter, with excitation wavelength of 544 nm and emission wavelength 
of 590 nm. Resorufin calibration curve, ranging from 25 nM to 400 nM, was prepared and 
analyzed. 
3.4.3 Plasma and tissue sample analysis.  The analysis of plasma samples from AHR 
agonist rat PK study (β-NF, I3C) were performed by Covance (Princeton, NJ).  See appendix for 
detailed descriptions of PK study and bioanalytical protocols. 
Plasma sample analysis of AHR antagonist study.  Plasma and tissue samples of AHR 
antagonist rat PK study were analyzed as described below.  Plasma samples were prepared on 
ice.  Calibration curve containing a cocktail solution with each analyte concentration, listed in 
Table 4, were made using stock solutions of caffeine (10 mg/mL), paraxanthine (1 mg/mL), 
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theobromine (290 μg/mL), and theophylline (1 mg/mL) in methanol and RUT (100 μg/mL) and 
CH223191 (100 μg/mL) in DMSO.  Blank (containing only caffeine-d9 as internal standard) and 
double blank (containing only the solvent used to dissolve internal standard) were also prepared.  
Quality control (QC) samples were prepared at the same time as plasma sample preparation.  
Plasma sample preparation.  Due to the high sensitivity of LC-MS/MS, high 
concentration (>10 µg/ml) samples were diluted by either 2 or 4-folds.  To 40 μL of plasma 
sample/standard, 80 μL of methanol containing 0.1% formic acid and 80 ng/mL caffeine-d9 and 
100 ng/mL nitro-rutaecarpine (internal standard for rutaecarpine), was added to precipitate the 
proteins.  The mixture was vortexed and centrifuged at 16,000 g for 20 minutes at 4 °C.  90 μL 
of the resulting supernatant was collected and transferred to HPLC vials with glass inserts and 
analyzed.  
Instrumentation.  Samples were injected at a flow rate of 0.5 mL/min into a Phenomenex 
Kinetex column (4.6 x 250 mm, 5 μ) or a Phenomenex Synergi 4 μ fusion column (2.5 x 250 
mm).  The assembly consisted of Agilent 1100 system (Agilent Technologies, Palo Alto, CA, 
USA) with API 3000 LC-MS/MS System, a triple quadrupole mass spectrometer equipped with 
an electron spray ionization source.  Column temperature was maintained at 20 °C.  The mobile 
phase for caffeine and its metabolites consisted of HPLC grade methanol and 0.1% formic acid 
in distilled water (1:3 v/v). An isocratic program was used for HPLC separation at a flow rate of 
0.5 mL/min with an injection volume of 20 μL. Quantification was performed using multiple 
reaction monitoring (MRM).  The mass transitions used for caffeine, paraxanthine, theophylline, 
theobromine and caffeine d-9 were positive ion mode with m/z 195.1 → 138.0, 180.1 → 124.0, 
180.9 → 123.9, 181.1 → 138.0 and 203.9 → 144.0, respectively; declustering potential of 41, 
41, 46, 36 and 41 V, respectively; entrance potential, all at 10 V; collision energy of 27, 27, 29, 
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27 and 35 V, respectively; and collision exit potential of 10, 8, 22, 10 and 12 V, respectively.  
Retention time of theobromine was 8-9, paraxanthine was 11-12, theophylline was 13-14, 
caffeine-d9 was 18-19, and caffeine was 19-20 minute.  Total run time was 21 minutes.  
The same samples were re-run with Phenomenex Synergi 4 μ fusion column (2.5 x 250 
mm) to measure RUT concentration.  The mobile phase for RUT consisted of HPLC grade 
methanol and 0.1% formic acid in distilled water (4:1 v/v).  An isocratic program was used for 
HPLC separation at a flow rate of 0.5 mL/min with an injection volume of 20 μL. Quantification 
was performed using multiple reaction monitoring (MRM).  The mass transitions used for RUT 
and nitro-rutaecarpine were positive ion mode with m/z 287.8 → 273.2 and 333.3 → 287.1, 
respectively; declustering potential of 81 and 36 V, respectively; entrance potential of 10 V; 
collision energy of 47 and 43 V, respectively; and collision exit potential of 16 and14 V, 
respectively.  
Calibration curves for caffeine, paraxanthine, theophylline, theobromine and RUT in rat 
plasma were derived from the regression of the peak area ratios relative to that of caffeine d9 
(nitro-rutaecarpine for rutaecarpine), with 1/x as the weighing factor. The respective QC samples 
were analyzed along with each batch of plasma samples.  Lower limit of quantitation (LLOQ) of 
caffeine, paraxanthine, theophylline and theobromine were 50 ng/mL.  LLOQ of RUT and CH = 
50 ng/mL and 50 ng/mL, respectively.  
3.4.4 Pharmacokinetic data analysis.  Pharmacokinetic data analysis.  
Pharmacokinetic (PK) parameters were calculated using WinNonlin Professional software, 
version 2.1 (Pharsight, Mountain View, CA).  Non-compartmental analysis for IV bolus input 
(Model 201) and extravascular input (Model 200) was employed to estimate caffeine’s PK 
parameters.  The AUC0-inf is the area under the curve from time zero hour to infinity.  t/1/2,z, is the 
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terminal half-life, calculated by /1/2,z =0.693/ λz, where  λz is the terminal slope.  MRT is the mean 
residence time.  
Clearance (CL). CL is the total clearance calculated by CL= 
𝐷𝐼𝑉
𝐴𝑈𝐶𝐼𝑉
.            
 
 
 
 Table 4: Calibration curve of rat plasma analysis of AHR antagonist rat PK study 
No. Caffeine 
(μg/mL) 
Paraxanthine 
(μg/mL) 
Theophylline 
(μg/mL) 
Theobromine 
(μg/mL) 
RUT 
(μg/mL) 
CH223191 
(μg/mL) 
1 0.05 0.025 0.01 
2 0.10 0.05 0.02 
3 0.25 0.125 0.05 
4 0.35 0.175 0.07 
5* 0.5 0.25 0.1 
6 1 0.5 0.2 
7* 2 1 0.4 
8 5 2 1 
9 7 3.5 1.4 
10* 9 4.5 1.8 
11 10 5 2 
*Were made for quality control (QC) samples as well.  
 
 
68 
 
Oral bioavailability calculation .  CL =
𝐷𝐼𝑉
𝐴𝑈𝐶𝐼𝑉
=
𝐹∗𝐷𝑃𝑂
𝐴𝑈𝐶𝑃𝑂
, rearrangement of the equation 
resulted in F=
𝐴𝑈𝐶𝑃𝑂∗𝐷𝐼𝑉
𝐷𝑃𝑂∗𝐴𝑈𝐶𝐼𝑉
.  For a parallel study, F value is calculated by averaging AUC and 
dosage values in each group to obtain a mean AUC and dosage values, which are then computed 
to obtain F, according to  F=
𝐴𝑈𝐶𝑃𝑂,𝑚𝑒𝑎𝑛∗𝐷𝐼𝑉,𝑚𝑒𝑎𝑛
𝐷𝑃𝑂,𝑚𝑒𝑎𝑛∗𝐴𝑈𝐶𝐼𝑉,𝑚𝑒𝑎𝑛
 .  Standard deviation is calculated by error 
propagation method.  
Fh is the fraction of drug that escapes liver first pass metabolism and is calculated by 
Fh=
𝐶𝐿
𝑄ℎ
, where Qh is an average liver blood flow in rats (55 mL/h/kg).   
3.4.5 MROD assay of rat liver samples.  Microsome sample preparation.  All sample 
containers were pre-chilled and samples were prepared on ice.  Approximately 1 g of liver tissue 
was finely chopped, followed by homogenization with a tissue homogenizer in homogenization 
buffer (8.53% sucrose, 1.1% potassium chloride and 1 mM EDTA in 0.1 M phosphate buffer pH 
7.4).  Homogenization was performed until tissues were completely suspended in the buffer. The 
homogenate was centrifuged at 4°C for 20 min at 9,000 g.  The post-mitochondrial supernatant 
(S9) fraction was collected without disturbing the pellet and transferred to ice-cold ultra-
centrifuge tubes and centrifuged at 105,000 g for 65 min at 4 °C to yield microsomal pellets.  
The supernatant was aspirated from the microsomal pellet, which was then homogenized in 1:1 
(w/v) re-suspension buffer (0.25 M sucrose in 0.1 M phosphate buffer pH 7.4,).  The resulting 
microsomes were transferred to ice-cold Eppendorf tubes and stored in -80°C until MROD assay 
analysis.  
MROD assay of rat liver microsome.  Methoxyresorufin-0-deethylase (MROD) assay41, 
88 was used to measure CYP1A2 activity in rat liver samples.  The activity of CYP1A2 in 
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different samples were measured as a rate of the O-dealkylation of 7-methoxyresorufin into 
resorufin in the presence of NADPH.  Resorufin can be detected using a fluorescence detector.  
Resorufin calibration samples were prepared in methanol, ranging from 39 to 5000 nM.  
Standards with blanks were prepared in duplicates.  For MROD assay, 25 μL of microsome 
samples were added to 75 μL of a 37°C preheated master mix solution to form a solution with 
the final concentration of 10 μM methoxyresorufin in 0.1 M phosphate buffer pH 7.4, with or 
without 5 mM NADPH.The resulting solution was incubated in a water bath at 37 °C for 1 hour, 
followed by addition of 200 μL of ice-cold methanol to quench the reaction.  Each sample was 
vortexed and centrifuged at 16,000 g for 10 min.  200 μL of the resulting supernatant was 
transferred to 96 well plates, which was then analyzed together with resorufin calibration curve 
samples by a fluorescence detector.  The formation of resorufin was monitored fluorometrically 
using an excitation wavelength of 544 nm and an emission wavelength of 590 nm.  
3.4.6 Statistical Analysis.  IBM SPSS statistics 25 software was utilized for statistical 
analysis.  Significant differences were determined by performing independent t- tests and one-
way ANOVA, followed by post hoc tests to determine the statistical significance difference, with 
* denoting p <0.05, ** denoting p < 0.01, *** denoting p < 0.001 and ns denoting not significant 
(p > 0.05).  
3.5 Result and Discussion 
 3.5.1 MROD Data of CH223191 effect in Hep3B cells.  Figure 14 and 11 show the data 
of MROD assays of Hep3B cells treated with RUT, CH, 3-MC, RUT + CH or 3-MC + CH.  The 
result shows that 1 μM RUT was able to induce the activity of Cyp1a2 and this induction was 
blocked by co-incubation of RUT with CH.  Similarly, CH was able to inhibit the induction of 
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Cyp1a2 by 3-MC.  The data is consistent with a published report34 that show that 10 μM CH can 
block RUT induced EROD activity in Hepa1c1c7 cells.   
 3.5.2 Effect of CH223191, an AHR antagonist, on caffeine’s systemic exposure in 
rats.  CH223191 plasma level in rats.  Figure 16 shows plasma concentrations of CH223191 
following oral administration of 5 mg/kg dose to rats daily for 5 days.   CH223191 Cmax ranges 
from 174 to 401 ng/mL, with Tmax of about 1 hour.  The mean CH223191 Cmax for all 4 groups of 
rat is 327 ng/mL, which is equivalent to 0.98 μM which is about 10 fold less than the effective 
concentration in Hep3B cells.   
Caffeine plasma concentration time profiles after IV and PO dosing. Figure 17 to 15 
show caffeine plasma concentrations after IV and oral caffeine administrations, respectively, in 
rats pretreated with either VEH, CH, RUT, or RUT + CH daily for 5 consecutive days.  Table 5 
and Table 6 show the results of non-compartmental analysis of caffeine plasma concentration vs. 
time data.   
After IV caffeine dosing, Figure 17 shows that CH has no effect on caffeine plasma 
concentrations, in rats pretreated with CH only or RUT + CH, as shown by overlapping plasma 
concentration time curves between VEH and CH rats, and between RUT and RUT + CH rats.   
After oral caffeine dosing, Figure 18 shows that CH also has no effect on caffeine plasma 
concentrations in rats pretreated with RUT + CH, as shown by overlapping plasma concentration 
time curves between RUT only or RUT + CH rats.  Caffeine plasma concentration time curves 
between VEH and CH treated rats group do not overlap, as shown in Figure 19, but Table 6 
shows that there are no statistical significance differences in PK parameters between VEH and 
CH treated rats or between RUT only and RUT + CH rats. 
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Figure 20 and Figure 21 show MROD assay data from microsomes prepared from livers 
harvested from rats treated with VEH, CH, RUT or RUT + CH, in IV and PO caffeine dose 
groups, respectively.  MROD assay data is consistent with the observed PK data.  The data show 
that CH treatment does not have an effect while RUT treatment increases Cyp1a2 activity, 
comparable to the activity level observed from livers from RUT treated rats in the 2015 PK study 
(RUT15), where rats were pretreated with RUT orally daily for 7 consecutive days.   
 
 
 
 
Figure 14: MROD assay data for the effect of 10 μM CH223191 (CH) on rutaecarpine (RUT) 
and 3-MC induced Cyp1a2 activity in Hep3B cells.  RUT (1 μM), CH (10 μM) and 3-MC (1 
μM). Data is presented as mean ± SD, n = 3/group.  ** denoting P < 0.01.*** denoting P < 
0.001. 
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Figure 15: MROD assay data for the effect of 0.5, 1 and 2 μM CH on RUT and 3-MC induced 
Cyp1a2 activity in Hep3B cells.  RUT (1 μM), CH (0.5, 1 or 2 μM) and 3-MC (1 μM). Data is 
presented as mean ± SD, n = 3/group.  ** denoting P < 0.01.  
 
 
 
 
Figure 16: CH223191 plasma concentrations following oral administration of 5 mg/kg dose to 
rats daily for 5 days.  RUT + CH, CAFIV = CH co-administered with 100 mg/kg RUT 
pretreatment, followed by IV caffeine (CAF) dosing; RUT + CH, CAFPO = CH co-administered 
with RUT pretreatment, followed by PO CAF dosing; CH CAFIV = CH pretreatment followed by 
IV CAF dosing; CH CAFPO = CH pretreatment followed by PO CAF dosing.  CH (5 mg/kg), 
RUT (100 mg/kg), CAFIV (15 mg/kg), and CAFPO (20 mg/kg).   Data is presented as mean ± SD, 
n = 4/group. 
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Both MROD and PK data show that CH223191 does not appear to block RUT effect on 
downstream Cyp1a2 activity.  It could be due to CH not reaching its effective in vivo 
concentration needed to exert its antagonistic AHR effect.  The Cmax of CH223191 is as 
mentioned in before is about 10-fold less than in vitro effective concentration.  Future studies 
with higher CH dose could be performed to see if higher exposure of CH in rats could antagonize 
RUT effect or if a different antagonist can block RUT effect. 
Figures 18-20 shows that RUT pretreatment significantly decreases caffeine AUC after 
IV and PO caffeine dosing.  Caffeine AUCs were decreased by approximately 60% and 80% 
after IV and PO dosing, respectively (Tables 5 and 6).  This data is consistent with previously 
observed caffeine data upon RUT pretreatment (2015 PK study).   Observed decrease in AUC 
after IV dosing is due to a higher caffeine CL in RUT (230% of VEH) compared to VEH treated 
rats.  Observed decrease in AUC after PO dosing is due to a higher caffeine CL and a decrease in 
oral bioavailability (47% of VEH) in RUT compared to VEH treated rats.  However, 
interestingly, in both VEH and RUT groups, caffeine appears to exhibit flip-flop kinetics, as 
indicated by different terminal slopes of IV and PO plasma concentration curves, which suggests 
that its absorption rate constant is greater than its elimination rate constant.  This is contrary to 
known caffeine kinetics in rats, as well as in human 38, 89.  Figures 21 and 22 show Simcyp 
simulated IV and PO caffeine plasma concentrations in human and rats, respectively.  The 
terminal slopes of IV and PO plasma concentration curves parallel each other in both species.  
Figure 23 shows the comparison of rat caffeine plasma concentration profiles after IV dosing 
from Simcyp simulated (Simulated), 2015 PK study with a single dose of VEH administered one 
day before caffeine dosing (2015 VEH), once daily doses of RUT in VEH for 7 days (2015 
RUT), once daily doses of VEH for 5 days for antagonist PK study (VEH) and once daily doses 
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of RUT in VEH for 5 days for antagonist PK study (RUT).  As expected, there are no major 
differences in the IV caffeine concentration profiles among Simulated, 2015 VEH and VEH 
groups, while RUT group has a steeper terminal slope compared to VEH, which indicates a 
higher elimination rate constant due to increased Cyp1a2 activity.  However, Figure 24 shows 
that caffeine concentration profiles from simulation is similar to concentration profiles from 
2015 VEH group but not (this) VEH group.  The differences between these two groups are the 
frequency of VEH (Cremophor EL: Ethanol: H2O=2:2:6) administration (once vs. 5-daily 
doses).  Figure 24 also shows that the terminal slopes between 2015 RUT (7 daily doses) and 
RUT (5 daily doses) are different, even though MROD data show that their Cyp1a2 activity 
levels are similar and their AUCinf,po (AUCinf-po,2015,7dose =6.6±2.0, AUCinf,po,5dose =8.8±4.9) are 
also similar. Currently, we do not know the reason for the observed differences. 
Data for caffeine metabolites (paraxanthine, theobromine and theophylline) are presented 
in Appendix and will be analyzed by another group member in the near future. 
Rutaecarpine plasma concentrations after IV and PO dosing.  We were not able to 
measure the concentration of RUT in plasma samples of rats pretreated with RUT since all 
plasma samples were below the lower limit of quantification (LLOQ = 50 ng/mL).   This 
indicates that the resulting plasma RUT level was low and yet, it was still able to exert its effect 
on caffeine PK. 
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Figure 17: Caffeine plasma concentrations following IV CAF dosing in rats pretreated with 
VEH, CH, RUT, or RUT + CH.   CH (5 mg/kg), RUT (100 mg/kg), and CAFIV (15 mg/kg).   
Data is presented as mean ± SD, n = 4/group. 
 
 
 
 
Figure 18: Caffeine plasma concentrations following PO CAF dosing in rats pretreated with 
VEH, CH, RUT, or RUT + CH.   CH (5 mg/kg), RUT (100 mg/kg), and CAFPO (20 mg/kg).   
Data is presented as mean ± SD, n = 4/group. 
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Table 5: PK parameters of caffeine following IV dosing in rats pretreated with VEH, CH, RUT, 
or RUT + CH. CH (5 mg/kg), RUT (100 mg/kg), and CAFIV (15 mg/kg).   Data is presented as 
mean ± SD, n = 4/group. * denoting P < 0.05 and **denoting P < 0.01.  
 
 
 
 
 
Figure 19: Cartesian plot of caffeine plasma concentrations following PO CAF dosing in rats 
pretreated with VEH, CH, RUT, or RUT + CH.   CH (5 mg/kg), RUT (100 mg/kg), and CAFPO 
(20 mg/kg).   Data is presented as mean ± SD, n = 4/group. 
 
 
 
Table 6: PK parameters of caffeine following PO dosing in rats pretreated with VEH, CH, RUT, 
or RUT + CH.   CH (5 mg/kg), RUT (100 mg/kg), and CAFPO (20 mg/kg).   Data is presented as 
mean ± SD, n = 4/group. * denoting P < 0.05. 
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Parameter VEH CH RUT RUT + CH 
AUCinf (g*h/mL) 40.3±9.3 33.5± 18.0 17.2± 3.5* 12.8±2.3* 
AUC (% of control) 100% 83% 42% 31% 
CL (mL/h) 103± 24 223± 195 237± 50* 313± 50** 
CL (% of control) 100% 216% 230% 303% 
MRTinf (h) 2± 0.6 1.8± 0.5 0.7±0.1* 0.7± 0.1* 
MRT (% of control) 100% 90% 35% 35% 
C0 (μg/mL) 18.5± 0.4 18.2± 7.9 20.1± 3.3 17.8± 2.0 
C0 (% of control) 100% 98% 108% 96% 
t1/2,Z (h) 1.5±0.4 1.0±0.5 0.4± 0.1** 0.4±0.1** 
t1/2,Z  (% of control) 100% 66.6% 26.7% 26.7% 
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Parameter VEH CH RUT RUT + CH 
AUCinf (g*h/ml) 41.6±18.6 45.3±7.6 8.8±4.9* 10.5±4.4* 
AUC (% of control) 100% 109% 21% 25% 
F 0.71±0.35 0.92±0.53 0.34±0.20 0.58±0.26 
F (% of control) 100% 130% 47% 81% 
Fh 0.88±0.03 0.75±0.2 0.72±0.05* 0.63±0.06* 
Fh (% of control) 100% 85% 82% 72% 
MRT (h) 4.2±1.5 2.7±0.45 2.5±0.8 2.5±0.7 
MRT (% of control) 100% 64% 60% 60% 
Cmax (μg/ml) 10.3±2.2 11.5±0.7 3.5±2.2* 3.4±2.4* 
Cmax (% of control) 100% 111% 34% 33% 
Tmax (h) 0.27±0.15 1±0* 0.58±0.42 0.89±0.19* 
Tmax % of control 100% 369% 215% 329% 
t1/2,Z (h) 2.9±0.9 1.5±0.5 1.3±0.5 1.7±0.7 
t1/2,Z (% of control) 100% 52% 45% 59% 
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Figure 20: MROD data from livers from rats pretreated with VEH, CH, RUT, or RUT + CH and 
dosed IV with caffeine.  VEH15 and RUT15 are livers from 2015 PK study with or without 7 
consecutive doses of Rut.  CH (5 mg/kg), RUT (100 mg/kg), and CAFIV (15 mg/kg).   Data is 
presented as mean ± SD, n = 4/group.  *** denoting P < 0.001 compared to VEH. 
 
 
 
 
Figure 21: MROD data from livers from rats pretreated with VEH, CH, RUT, or RUT + CH and 
dosed PO with caffeine.  CH (5 mg/kg), RUT (100 mg/kg), and CAFPO (20 mg/kg).   Data is 
presented as mean ± SD, n = 4/group.  ** denoting P < 0.01 compared to VEH. 
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Figure 22: IV and PO caffeine plasma concentration comparisons in rats pretreated with VEH or 
RUT.  RUT (100 mg/kg), CAFIV (15 mg/kg), and CAFPO (20 mg/kg).  Data is presented as mean 
± SD, n = 4/group. 
 
 
 
Figure 23: IV and PO caffeine plasma concentration comparisons in rats pretreated with VEH.   
CAFIV (15 mg/kg), and CAFPO (20 mg/kg).  Data is presented as mean ± SD, n = 4/group.  
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Figure 24: IV and PO caffeine plasma concentration comparisons in rats pretreated with RUT.   
RUT (100 mg/kg), CAFIV (15 mg/kg), and CAFPO (20 mg/kg).  Data is presented as mean ± SD, 
n = 4/group. 
 
 
 
3.5.3 Effect of AHR agonists on caffeine’s systemic exposure in rats.  Caffeine 
plasma concentration after PO dosing.  Figure 29 shows caffeine plasma concentrations after 
oral caffeine dosing in rats pretreated with either VEH, β-NF or I3C daily for 5 consecutive days 
and Table 7 shows the calculated PK parameters.  Caffeine concentration profile in VEH group 
is not as expected.  It appears to plateau after 1 hour, resulting in more than 50% extrapolated 
AUC.  Therefore, AUC0-tlast(10h) is compared and both β-NF and I3C show reduced AUC0-tlast(10h) 
compared to VEH.  Caffeine F values in β-NF and I3C pretreated rats could not be calculated 
since the corresponding IV caffeine dosing arms were not performed.  However, comparison of 
caffeine concentrations from this agonist study with the antagonist study show that caffeine 
exposure is comparable between β-NF and CH and between RUT and I3C treated rats (Figure 30 
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and Table 8). No statistical analysis was done for Table 8 since the animal studies were 
performed in different places and at different times. 
Rutaecarpine, β-NF and I3C plasma concentrations after PO dosing.  We were not able 
to measure the concentration of RUT or β-NF in plasma samples of rats pretreated with RUT or 
β-NF since all plasma samples were below the lower limit of quantification (LLOQ = 3.05 
ng/mL for both RUT and β-NF).  I3C levels were not available as well due to the challenge in 
developing the LC/MS-MS method. 
 
 
Figure 25: Simcyp simulated IV and PO caffeine plasma concentrations in human.  CAFIV (100 
mg), and CAFPO (150 mg).  N = 10/group. 
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Figure 26: Simcyp simulated IV and PO caffeine plasma concentrations in rats.  CAFIV (15 
mg/kg), and CAFPO (20 mg/kg).    
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Figure 27: IV dose caffeine plasma concentration comparisons in rats pretreated with a single 
dose of VEH (2015 VEH), 5 daily doses of VEH (VEH), 7 daily doses of RUT (2015 RUT), 5 
daily doses of RUT (RUT) or no pretreatment (Simulated).    
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Figure 28: PO dose caffeine plasma concentration comparisons in rats pretreated with a single 
dose of VEH (2015 VEH), 5 daily doses of VEH (VEH), 7 daily doses of RUT (2015 RUT), 5 
daily doses of RUT (RUT) or no pretreatment (Simulated).    
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Figure 29: Caffeine plasma concentration comparisons following oral dosing in rats pretreated 
with 5 consecutive doses of VEH, β-NF or I3C.   β-NF (120 mg/kg), I3C (167 mg/kg), and one 
dose of CAFPO (20 mg/kg). Data is presented as mean ± SD, n = 5/group. 
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Figure 30: Caffeine plasma concentration comparisons following oral dosing in rats pretreated 
with VEH-Ant (antagonist study), VEH (agonist study), RUT, β-NF or I3C. RUT (100 mg/kg), 
β-NF (120 mg/kg), I3C (167 mg/kg) orally, and CAFPO (20 mg/kg).   Data is presented as mean 
± SD, n = 5/group for AHR agonist study, n=4/group for AHR antagonist study. Inner figure is 
the data blow up from 0-1 h.  
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Table 7: PK parameters of caffeine following PO dosing in rats pretreated with VEH, β-NF, or 
I3C. -NF (120 mg/kg), I3C (167 mg/kg), and CAFPO (20 mg/kg).  Data is presented as mean ± 
SD, n = 5/group. *denoting P < 0.05, ** denoting P < 0.01 and *** denoting P < 0.001, compared 
to VEH. 
 
 
 
 
 
 
 
 
 
 
Table 8: PK parameters of caffeine following PO dosing in rats pretreated with CH, β-NF, RUT 
or I3C.  CH (5 mg/kg), RUT (100 mg/kg), β -NF (120 mg/kg), I3C (167 mg/kg) 5 consecutive 
doses, and CAFPO (20 mg/kg) one dose only.  Data is presented as mean ± SD, n = 4-5/group.  
Parameter CH -NF RUT I3C 
AUC0-inf 
(h*μg/mL) 
45.3±7.6 44.04±5.63 8.82±4.85 12.1±2.44 
Cmax (μg/mL)  11.5±0.7 11.0±1.9 3.5±2.2 5.5±1.1 
Tmax (h) 1±0 1.0±0 0.58±0.42 0.7±0.48 
t1/2,z (h) 1.5±0.5 1.4±0.54 1.3±0.5 1.2±0.23 
F 0.92±0.53 N/A 0.34±0.20 N/A 
CL/F (mL/h)  130±21 138±16.9 887±456 513±86.7 
MRTINF (h) 2.7±0.45 3.1±0.44 2.5±0.8 2.00±0.22 
 
  VEH -NF I3C 
AUC0-10h (h*μg/mL) 105 ± 10.9 43.5±6*** 12.1±2.4*** 
AUC0-inf (h*μg/mL) 236.78±42.7 44.04±5.63** 12.09±2.44** 
AUC%Extrap (%) 53.1±9.96 1.2±1.69 0.4±0.34 
Tlast (h) 10.0±0.00 10.0±0.00 10.0±0.00 
Cmax (μg/mL)  12.4±1.4 11.0±1.9 5.5±1.1*** 
Tmax (h) 4.0±2.24 1.0±0.00** 0.7±0.48** 
t1/2,z (h) 10.8±2.76 1.4±0.54* 1.2±0.23* 
MRTINF (h) 16.2±3.88 3.1±0.44*** 2.0±0.22*** 
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3.6 Conclusion and Future Studies 
AHR signaling pathway appears to be involved in reducing caffeine exposure in rats 
upon RUT, -NF and I3C pretreatment for 5 consecutive days prior to caffeine dosing.  Future 
PK studies need to be performed with caffeine IV dose after -NF and I3C treatment, to 
determine the contribution of reduced oral F vs. reduced CL to observed decrease in AUCpo.  5 
mg/kg oral CH223191 dose for 5 consecutive days prior to caffeine dosing was not able to 
antagonize RUT effect.  Future studies need to be performed to determine if a higher CH 223191 
dose or a different antagonist can antagonize the effect of RUT, -NF or I3C on caffeine PK in 
rats. 
The vehicle (Cremophor EL: Ethanol: H2O=2:2:6) used for RUT, CH, -NF and I3C 
studies appears to have an effect on caffeine oral (but not IV) PK profiles upon multiple dosing 
(but not after a single dose).  Future studies need to be performed to see if this observation is real 
and the potential mechanisms. 
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Chapter 4: Pharmacokinetics Study of Caffeine With and Without Rutaecarpine in AHR 
Wild Type and Knock Out Mice  
4.1 Overview 
Rutaecarpine has been shown to increase the systemic clearance (CL) of caffeine by as 
much as 134 % and reduce its oral bioavailability (F) in rats by 37%.  We hypothesize that these 
changes are mediated via AHR.  We believe the mechanism by which rutaecarpine increases the 
CL of caffeine is as follows: upon rutaecarpine binding to AHR, the AHR signaling pathway is 
activated, which induces the expression of Cyp1a2, a downstream gene in the AHR signaling 
pathway.  Cyp1a2 is a CYP450 enzyme involved in metabolizing caffeine in rats and higher 
Cyp1a2 enzyme level means higher intrinsic clearance (CLint) value for caffeine.  Caffeine is a 
low hepatic extraction ratio (ERh) drug in rats and higher CLint leads to higher hepatic clearance 
value (since CLh is proportional to fu x CLint for low ERh drugs), which in turn leads to higher 
total CL value for caffeine in rats since hepatic metabolism is a dominant elimination pathway 
for caffeine.  However, the mechanism by which rutaecarpine decreases the oral bioavailability 
of caffeine is not understood but we believe it is also mediated by AHR pathway.  As shown 
earlier, rat PK study data has shown that two other AHR agonists, β-NF and I3C, also reduce the 
oral exposure of caffeine in rats.   
To further test the hypothesis that AHR pathway is involved in both the reduction of 
caffeine oral bioavailability and the increase in caffeine systemic clearance, a caffeine 
pharmacokinetic study, with and without rutaecarpine, was conducted in wild type (WT) and 
AHR knock out (KO) mice.  According to the hypothesis, there will be no observable differences 
in the pharmacokinetic profiles of caffeine, with and without rutaecarpine, in AHR KO mice 
since no AHR is present to bind to rutaecarpine to activate AHR signaling pathway so no 
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downsteam genes will be induced, including Cyp1a2.  In WT mice, we expect to see higher CL 
and lower F values of caffeine upon rutaecarpine co-administration, as observed in rats.  
4.2 Study Design 
A constitutive AHR KO (C57BL/6- Ahrtm1,2Arte) 44, 90, 91 and WT (C57BL/6) mice were 
used in the study.  Both AHR KO and WT mice were randomized into two groups: rutaecarpine 
(Rut) and vehicle (Veh) groups with n = 4 and n = 5 for AHR KO and WT mice, respectively.  A 
cross-over study design was employed. Caffeine was dosed intravenously first, followed by oral 
caffeine dosing, after a 7-days wash out period. WT and KO mice were pretreated orally with 
100 mg/kg rutaecarpine (a suspension in ethanol, cremophor EL and water with 20:20:60 v/v, for 
Rut group) or vehicle (cremophor EL, ethanol and water with 20:20:60 v/v, for Veh group) daily 
for 5 consecutive days before a 30 mg/kg intravenous dose of caffeine (in saline) was given. 
Blood samples were taken right after caffeine administration at 0.033, 0.5, 1, 2, and 4 hours 
within Following a 7-day washout period, 5 days of either 100 mg/kg rutaecarpine or vehicle was 
administered again, followed by a 40 mg/kg oral caffeine administration. Another set of blood 
samples was taken right after caffeine administration at 0.033, 0.5, 1, 2, and 4 hours.  Plasma 
concentrations of rutaecarpine, caffeine and its major three metabolites, paraxanthine, 
theophylline, and theobromine, were measured. 
4.3 Material and Method 
4.3.1 Animal.  AHR knockout mice, C57BL/6- Ahrtm1,2Arte were purchased from Taconic 
(Rensselaer, New York).  Ruteacarpine was donated by Linnet Biopharmaceuticals.  The AHR 
knockout mice study and bioanalytical analysis were performed at Genentech Inc. (South San 
Francisco, CA).  The wild type (WT) mice study and bioanalytical analysis were performed at 
Covance Laboratories (Princeton, NJ).  
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Table 9: Expected result of mice study with or without pretreatment of 100 mg/kg orally 
administered RUT in WT and AHR KO mice. 
 
 
 
 
 
 
 
 
 
4.3.2 PK parameter calculation.  Pharmacokinetic parameter calculations were 
performed as previously described in chapter 3, except the calculation of F values.  Because this 
is a cross over study, the F value of each individual mouse can be calculated by F=
𝐴𝑈𝐶𝑃𝑂∗𝐷𝐼𝑉
𝐷𝑃𝑂∗𝐴𝑈𝐶𝐼𝑉
.  
Next, mean F value was obtained by taking the average of all 4 or 5 mice, while in the rat study, 
mean F value was calculated by first averaging values of all four parameters (AUCpo, Dpo, AUCiv 
and Div) that were obtained in the study.  
Group Mice Strain Description Size (n) Expected Changes 
CL F 
1 WT VEH 5   
2 WT RUT 5    
3 KO VEH 4   
4 KO RUT 4   
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4.3.2 Total RNA extraction.  Total RNA from liver tissues of AHR WT and KO was 
isolated and purified using Direct-zol RNA Miniprep Plus kit containing Tri Reagent (Zymo 
Research, Irvine, CA) according to the manufacturer’s protocol, with in-column DNase I 
treatment.  Liver samples were homogenized with Bullet Blender Storm 24 with ZrOB05 beads 
(Next Advance, Averill Park, NY).  RNA was eluted with 100 µl of DNase/RNase-Free water.  
Total RNA concentration and A260/280 ratio were measured with Take3 Epoch Microplate 
spectrophotometer (BioTek, Winooski, VT).  RNA integrity was checked by running RNA 
samples in 1.2% Lonza flashgel system RNA cassette (Lonza, Swiss Alps, Switzerland) in RNA 
flashgel dock system.  Bands were visualized with Bio-Rad Chemdoc SYBR safe software (Bio-
Rad, Hercules, CA).  RNA was stored at -80 °C freezer. 
4.3.3 Complementary DNA synthesis.  RNA samples were diluted to the same 
concentration before cDNA synthesis.  A second genomic DNA removal step was performed and 
cDNAs were synthesized with iScript gDNA Clear cDNA synthesis kit (Bio-Rad, Hercules, CA) 
according to the manufacturer’s protocol.  A no reverse transcriptase reaction (NRT) was 
performed along with cDNA synthesis step.  Genomic DNA removal and cDNA reactions were 
performed in clear low-profile thin-wall polypropylene 0.2 ml 8-tube strips with optical caps 
(Bio-Rad, Hercules, CA) with CFX Connect Real-Time System (Bio-Rad, Hercules, CA).   
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4.3.4 Realtime PCR reaction. Taqman PCR primer/probes for mouse Cyp1a2 
(Mm00487224_m1), Hbms (Mm01143545_m1) and B2m (Mm00437762_m1) reference genes 
used for PCR reactions were from Applied Biosystems (Foster City, CA).   PCR efficiency of the 
single and multiplex reactions were calculated using at least 1,000 fold cDNA dilution series.  
PCR reactions were performed using iTaq Universal Probes Supermix (Bio-Rad, Hercules, CA) 
according to the manufacturer’s protocol (see Appendix) with CFX Connect Real-Time System 
(Bio-Rad, Hercules, CA) in hard-shell thin-wall 96-well skirted PCR Plates (Bio-Rad, Hercules, 
CA).  The cycling conditions were as follows: 1 cycle of 50 °C for 2 minutes, another cycle at 95 
°C for 10 minutes and then 40 cycles of 95 °C for 15 s and 60 °C for 60 s.  Each cDNA sample 
was run in triplicate and a single no RT control reaction was performed with no RT cDNA 
samples. 
4.3.5 Data analysis. Normalized gene expression was calculated using CFX Manager 
software (Bio-Rad, Hercules, CA). 
4.4 Result 
4.4.1 RT-PCR experiment data. Figure 31 and Figure 33 show the amplification plots 
of mouse Cyp1a2 target gene with B2m and Hbms reference genes, respectively, for PCR 
efficiency test.  PCR efficiency for both all three genes are within the accepted 90-110% range 
(Figures 28 and 30). 
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Figure 31:  Amplification plot of mouse Cyp1a2 with B2m reference gene for PCR efficiency 
test. 
 
 
 
  
Figure 32:  Plot of log cDNA starting quantity vs. Cq plot for mouse Cyp1a2 with B2m reference 
gene PCR efficiency test 
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Figure 33:  Amplification plot of mouse Cyp1a2 with Hbms reference gene for PCR efficiency 
test. 
 
 
 
 
Figure 34:  Plot of log cDNA starting quantity vs. Cq plot for mouse Cyp1a2 with Hbms 
reference gene PCR efficiency test 
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Table 10 and Figure 35-35 show the relative normalized expression of mouse Cyp1a2 
mRNA, with B2m and Hbms reference genes, in livers of WT and AHR KO mice pretreated 
daily with either VEH or RUT for 5 days.  The data show that mouse Cyp1a2 mRNA expression 
is induced 5-fold (with B2m) or 8-fold (with Hbms) in WT RUT treated mice, but no induction is 
observed in RUT treated AHR KO mice.  The relative normalized expression of mouse Cyp1a2 
mRNA in AHR KO (VEH) appears to be about half of WT mice (VEH).   
 
 
 
Table 10: Relative normalized expression of mouse Cyp1a2 mRNA in livers of WT and AHR 
KO mice pretreated with VEH or RUT daily for 5 days 
 
 
Reference 
Gene 
Cyp1a2 Relative to WT VEH (AVG 
±SEM) 
 
   
 
 WT_VEH B2m 1.00±0.07  
 WT_RUT B2m 5.34±0.38***  
 KO_VEH B2m 0.50±0.08**  
 KO_RUT B2m 0.25±0.03***  
 
   
 
 WT_VEH Hbms 1.00±0.08  
 WT_RUT Hbms 7.71±0.73***  
 KO_VEH Hbms 0.53±0.03**  
 KO_RUT Hbms 0.35±0.04***  
Normalized expression relative to WT vehicle control-B2m or Hbms reference gene. **p<0.1, 
***p<0.001. 
 
 
 
97 
 
 
Figure 35: Relative normalized expression of mouse Cyp1a2 mRNA with B2m reference gene in 
livers of WT and AHR KO mice pretreated daily with VEH or RUT for 5 days. 
 
 
 
 
  
Figure 36: Relative normalized expression of mouse Cyp1a2 mRNA with Hbms reference gene 
in livers of WT and AHR KO mice pretreated daily with VEH or RUT for 5 days. 
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4.4.2 PK study data.  Caffeine plasma concentration vs. time profiles following 
intravenous (IV) dose after pretreatment of WT mice with 100 mg/kg rutaecarpine (RUT) or 
vehicle (VEH) was shown in Figure 37.  Caffeine pharmacokinetic parameters following IV 
caffeine dosing in both WT and AHR KO mice are summarized in Table 11.  The area under the 
curve (AUC) and clearance (CL) show a significant difference (between VEH (AUCinf,Veh,WT = 
79.5 ± 11.7 h*μg/mL, CLVeh,WT =10.4 ± 1.24 mL/h ) and RUT (AUCinf,Rut,WT= 53.4 ± 7. 1 
h*μg/mL, CLRut,WT =15.02 ± 2.02 mL/h)), which is consistent with observed RUT effect on 
caffeine kinetics in rats.  In WT mice, RUT decreased AUCIV by about 33% (p = 0.03), and 
increased CL by about 50% (p = 0.002). Furthermore, in addition to changes in AUC and CL 
values, there are significant differences in Clast, t1/2, and MRT values between VEH and RUT 
groups, which are consistent with induced Cyp1a2 activity upon RUT treatment via AHR 
pathway.  In contrast, no significant differences are observed in caffeine PK parameters in AHR 
KO mice between VEH and RUT groups, which is expected if RUT mediated changes are 
mediated via AHR pathway.  
Figure 38 shows caffeine plasma concentration vs. time profiles of orally dosed caffeine 
following pretreatment of WT mice with 100 mg/kg RUT or VEH solution. Caffeine 
pharmacokinetic parameters after PO caffeine dose in both WT and AHR KO mice are 
summarized in Table 12.  RUT treatment decreased caffeine AUCPO by about 67% (p < 0.001), 
which is consistent with observed RUT effect in rats.  With RUT pretreatment, caffeine oral 
bioavailability (F) value is decreased by about 49 % (p = 0.004), concentration at last time point 
(Clast) decreased by 84% (P = 0.003), and mean resident time (MRTlast) decreased by 16% (P = 
0.005) in WT mice, while 30% decrease in  Cmax was not statistically significance, due to large 
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standard deviations in VEH group   (Cmax,Veh,=51.2 ±22.7 μg/ml, Cmax,Rut 15.7 ± 6 μg/ml).  As in 
IV dosing, no significant differences are observed between VEH and RUT in AHR KO mice.  
Figure 41 and Figure 42 show the comparison of caffeine plasma concentrations between 
WT and AHR KO mice, with either VEH or RUT pretreatment.  The data show that in VEH 
group, caffeine is eliminated faster in WT compared to AHR KO mice (CLveh,wt = 10.4±1.24 
mg/h vs. CLveh,ko 3.9±1.29 ml/h in WT and AHR KO mice, respectively).  This is consistent with 
the observed lower Cyp1a2 mRNA level in AHR KO mice compared to WT.  The data shows Fh 
value are similar, ranging from 0.89 to 0.97, even though there is statistic significant between 
VEH and RUT in WT mice, however, the difference is less than 5% which keeps caffeine as a 
low hepatic extraction molecule.  The data also shows that caffeine F value is less in VEH 
treated AHR KO mice compared to WT mice (Table 12).  This could be the consequence of the 
absence of AHR in AHR KO mice, though by which mechanism this reduced caffeine absorption 
is mediated is unknown.  However, this is consistent with the observation that RUT, an AHR 
ligand, could reduce caffeine F.   
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Figure 37: Caffeine plasma concentrations following 30 mg/kg IV caffeine dose with VEH or 
100 mg/kg RUT pretreatment in WT mice. Data is presented as mean ± S.D. (n = 5/group). 
 
 
 
 
Figure 38: Caffeine plasma concentrations following 30 mg/kg IV caffeine dose with VEH or 
100 mg/kg RUT pretreatment in AHR KO (constitutive AHR C57BL/6- Ahrtm1,2Arte) mice. Data 
is presented as mean ± S.D. (n = 4/group).  
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Table 11: Average pharmacokinetic parameters of caffeine following 30 mg/kg caffeine administered intravenously (IV) in the 
presence and absence of 100 mg/kg orally administered rutaecarpine in WT and AHR KO mice.  
*p < 0.05.  **p<0.01, ***P<0.001, n=5 for wild type mice. n=4 for AHR knock out mice. 
 Wild Type Mice AHR Knock Out Mice 
 Veh Rut Rut/Veh % Veh Rut Rut/Veh % 
AUCinf (h*g/mL) 79.5 ± 11.7 53.4 ± 7.1* 67.1% 217.3 ± 116.8 248.3 ± 115.0 114% 
 
CL (mL/h) 10.4 ± 1.24 15.02 ± 2.02** 149.4% 3.9 ± 1.29 4.5 ± 0.17 
 
124% 
 
C4h(μg/ml)  5.4 ± 2.0 0.6 ± 0.15** 11.1% 16.8 ± 5.2 18.4 ± 8.2 
 
109% 
 
C0(μg/ml)  29.1 ± 5.9 40.4 ± 21.1 138.7% 33.4± 3.8 46.6 ± 17.2 
 
140% 
 
t1/2,z  1.47 ± 0.33 0.59 ± 0.052*** 40.3% 4.24 ± 2.34 5.37 ± 1.13 
 
127% 
 
Fh 0.93 ± 0.01 0.89 ± 0.01** 95.7% 0.97± 0.01 0.946 ± 0.0446 100.0% 
 
MRTinf (h)  2.21 ± 0.42 1.12 ± 0.069*** 50.7% 6.11 ± 3.37 7.57 ± 1.81 
 
124% 
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Figure 39: Caffeine plasma concentrations following 40 mg/kg PO caffeine dose with VEH or 
100 mg/kg RUT pretreatment in WT mice. Data is presented as mean ± S.D. (n = 5/group). 
 
 
 
 
Figure 40: Caffeine plasma concentrations following 40 mg/kg PO caffeine dose with VEH or 
100 mg/kg RUT pretreatment in AHR KO (constitutive AHR C57BL/6- Ahrtm1,2Arte) mice. Data 
is presented as mean ± S.D. (n = 4/group).
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 Table 12: Average pharmacokinetic parameters of caffeine following 40 mg/kg caffeine administered orally in the presence 
and absence of 100 mg/kg orally administered rutaecarpine in WT and AHR KO mice 
 **p<0.01, ***P<0.001, n=5 for wild type mice. n=4 for AHR knock out mice.  #data was got from one mouse. 
 
  Wild Type Mice AHR Knock Out Mice 
  VEH RUT RUT/VEH% VEH RUT RUT/VEH% 
 
AUC0-inf (h*g/mL) 108 ± 27.7 34.6± 12.9** 32.0% 152 ± 29.5 242 ± 80.6 159% 
 
C4h (μg/mL) 9.93 ± 3.14 1.6 ± 0.826** 16.3% 14.5 ±3.3 18.1 ± 3.3 125% 
 
Cmax (μg/mL) 22.7 ± 8.13  15.7 ± 5.96 69.2% 22.9 ± 5.5 24.1 ± 2.6 105% 
 
Tmax  1.20 ± 0.447 1.20 ± 0.447 100.0% 1.63 ± 0.75 1.63 ± 0.75 100.0% 
 
MRT4h (h) 1.90 ± 0.0536 1.59 ± 0.177** 83.7% 1.92   2.00  104% 
 
F  0.92 ± 0.18 0.47 ± 0.14** 51.1% 0.602 ± 0.215 0.615 ± 0.223 102% 
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Figure 41: Comparison of caffeine plasma concentrations following IV dosing after VEH or 
RUT pretreatment in WT and AHR KO mice. Each value represents the mean ± S.D. (n = 5 for 
WT, n = 4 for AHR KO). 
 
 
 
 
Figure 42: Comparison of caffeine plasma concentrations following PO dosing after VEH or 
RUT pretreatment in WT and AHR KO mice. Each value represents the mean ± S.D. (n = 5 for 
WT, n = 4 for AHR KO). 
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4.4.3 Rutaecarpine in vivo level in mice.  As in the rat studies, we were not able to 
measure the concentration of RUT in plasma samples of mice pretreated with RUT since all 
plasma samples were below the lower limit of quantification (LLOQ = 50 ng/mL).  This 
indicates that the resulting plasma RUT level was low, and yet it was still able to exert its effect 
on caffeine PK in WT mice. 
4.5 Disscussion 
 RUT has no effect on caffeine PK in AHR KO mice, which is consistent with recent 
findings that RUT upregulates AHR downstream gene battery in WT but not in AHR KO mice44.  
RUT pretreatment decreases caffeine AUCIV and AUCPO by 33% and 67%, respectively, 
suggesting that an increase in clearance contributes 1/3 while another 1/3 of AUC decrease in 
AUCPO is contributed by a decrease in oral bioavailability.  This is consistent with RT-PCR 
result that RUT induced 5-7 fold cyp1a2 mRNA suggesting that AUCIV decreases due to 
increases level of enzyme.  The lower level of cyp1a2 (50% or 25% compare to WT-VEH) in 
AHR KO mice than the WT mice explains why the caffeine’s clearance is lower in AHR KO 
mice than in WT mice.  
 The lack of rutaecarpine effect on caffeine PK parameters after IV and PO caffeine 
dosing in AHR KO mice suggested that RUT mediated decrease in caffeine’s oral bioavailability 
and an increase in clearance are both AHR dependent.  F = Fa x Fg x Fh, therefore, reduced F 
observed could be due reduced Fa or Fg or Fh or a combination of those factors.  Fh = CLh/Qh and 
even though Fh values between VEH and RUT in WT mice show statistical significance 
differences, the actual difference is negligible (Fh, RUT,WT/ Fh, VEH,WT = 96%) so increase in CL 
does not significantly affect caffeine F, as expected since caffeine is a low CLint drug in mice.   
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For AHR KO mice, no significant differences are observed on caffeine’s oral 
bioavailability (F), with or without RUT, with FKO,Veh = 0.59±0.23 and FKO,Ru t= 0.62±0.22. 
Due to limited amount of blood that can be sampled in a PK study, samples were only 
obtained up to 4 hours, which was not long enough to fully capture the PK of metabolites.  
Hence no metabolite analysis was performed, and raw metabolite data are presented in the 
Appendix C.  
4.6 Conclusion and Future Directions 
RUT pretreatment lowers caffeine F and increase CL in WT, but not AHR KO mice.  
Therefore, AHR pathway appears to be involved in the observed changes in caffeine PK upon 
RUT treatment.  The increase in CL is due to an increase in Cyp1a2 activity via induction of 
Cyp1a2 enzyme upon RUT binding to AHR, triggering the activation of AHR downstream 
genes.  However, the mechanism by which AHR reduces caffeine oral F is not known.  Caffeine 
has high oral bioavailability in the absence of pretreatment, which indicates that it has high Fa, Fg 
and Fh values.  We have shown that Fh remains high with RUT treatment, therefore, reduced F 
could be due to a decrease in Fa or Fg or both.  Future studies need to be performed to tease out 
the possible mechanism by which AHR mediated reduced F of drugs. 
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Chapter 5: Summary and Future Directions 
5.1 Summary of AHR Studies 
Pichia pastoris expression system is a convenient and low cost system to express 
recombinant AHR and ARNT proteins for in vitro functional studies.  However, the purity and 
yield of Pichia expressed AHR and ARNT need to be improved in order to be able to attain 
sufficient AHR and ARNT for crystallization to study their protein structures.  Better 
understanding of AHR and ARNT protein structures, and their signaling pathways could provide 
more insight for disease therapy and drug design.    
PK studies in rats and mice with AHR agonists and AHR KO mice show that AHR is 
likely to be involved in decreasing caffeine’s oral bioavailability.  Rats and mice PK study data 
indicate that rutaecarpine decreases caffeine’s systemic oral exposure through two pathways.  
One pathway is by increasing liver metabolism and the other one is by decreasing oral 
bioavailability.  Increased in clearance is due to induction of Cyp1a2 enzyme.  However, the 
exact mechanism how rutaecarpine, via AHR, lowers caffeine’s oral bioavailability is unknown.   
To our knowledge, this is the first study that shows AHR’s involvement in affecting 
caffeine bioavailability.  The result suggests that AHR regulation pathway may be important in 
modulating oral bioavailability of clinically administered drugs.  
5.2 Future Directions 
 To further confirm the role of AHR in affecting caffeine oral bioavailability, the IV arm 
of -NF and I3C studies need to be performed in rats to determine how much of observed 
reduction in oral caffeine exposure after PO caffeine dosing to rats pretreated with b-NF and I3C 
is due to reduction in F value.  A PK study with a higher dose of CH223191 or a different AHR 
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antagonist could be performed to see if RUT effect on caffeine PK can be blocked.  PK studies 
could be performed to determine if AHR agonists will have effect on oral bioavailability of other 
compounds, besides caffeine.  A human clinical PK study could be performed to see if the 
observed effects in rats and mice will also be observed in human.  More studies need to be 
performed to determine the exact mechanism by which AHR affects oral bioavailability.   
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 APPENDIX A: METHODOLODY 
 
 
Protein Quantitation.  
 
Bicinchoninic Acid Assay (BCA) is used to determine the total protein concentration in a 
solution. It is exhibited by a color change of the sample solution from green to purple in 
proportion to protein concentration, which is then measured using colorimetric techniques. The 
mechanism involved is the conversion of Cu2+ to Cu+ by protein under alkaline conditions. The 
reaction resulted in the development of an intense purple color with an absorbance maximum at 562 
nm. Since the production of Cu+ in this assay is a function of protein concentration and incubation 
time, the protein content of unknown samples may be determined spectrophotometrically by 
comparison with known protein standards. This is a water soluble complex and is nearly linear with 
increasing protein concentrations over an extensive working range of 0.02 to 2 mg/mL.  
Preparation of Standards and Samples.  
A standard calibration curve for bovine serum albumin (BSA) with seven concentrations, 
ranging from 0-1.5 mg/mL, were prepared in duplicate. All serial dilutions were made with 0.1 M 
phosphate buffer. Liver microsome samples were diluted 40X with 0.1 M phosphate buffer to a final 
volume of 80 μL. 10 μL of standards and 10 μL microsome samples were added individually into 
each well of 96-well plate. With a multi-channel pipetter, 190 μL of Pierce reagent A and B mixture 
(50:1, respectively) was added to each well (containing samples or standards). The plate was then 
placed on a shaker for about 5 min and incubated at 37 °C for 30 min, after which the reactions were 
analyzed at 562 nm using Tristar LB 941 microplate spectrophotometer. The concentrations of 
homogenates obtained from BCA assay were normalized to 10 mg/mL. 
Bioanalytical Analysis for Caffeine and Rutaecarpine and β-NF Done at Covance.  
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All the compound concentrations in blood and liver were determined by LC-MS/MS, 
which includes a Shimadzu CBM-20A controller with SIL-30AD pumps, a Shimadzu Nexera X2 
autosampler with a CTO-20AC column oven (Shimadzu, Columbia MD) and a AB Sciex API 
5500 quadrupole ion trap mass spectrometer (Applied Biosystems, Foster City, CA). Blood was 
diluted 5-fold with EDTA water. Following protein precipitation with 4-fold volume of 
acetonitrile containing loperamide and caffeine-d9 as the internal standards. The supernatant was 
diluted 3-fold prior to being injected. The caffeine metabolites (paraxanthine, theophylline and 
theobromine) were injected onto an Agilent Zorbax SB-Aq column (50x4.6 mm with 3.5um 
particle size). Caffeine and rutaecarpine were injected onto a Waters XBridge C18 column (50 x 
2mm with 3.5um particle size). The aqueous mobile phase was water with 0.1% formic acid (A) 
and the organic mobile phase was acetonitrile with 0.1% formic acid (B). The gradient for 
caffeine metabolites was the following: 35% for the first 0.01 minute, increased to 40% at 3 
minutes, then increased to 98% at 3.3 minutes, where it maintained at 98 % for 1 minute, then 
finally decreased back to 35% at 4.4 minutes. The total run time was 5 minutes at flow rate of a 
mix of 0.8 and 1.2ml/min. The gradient for caffeine and rutaecarpine was the following: 10% B 
for the first 0.01 minutes, increased to 98% B from 0.01 to 1.1 minute, maintained at 98 % B for 
0.4 minute and decreased to 10 % B within 0.1 minutes. The total run time was 2 minutes with 
flow rate at 1.2 ml/min. The ionization was conducted in the positive ESI ion mode using m/z 
181.100->124.100 for paraxanthine and theophylline, 181.100->138.100 for theobromine, 
288.300->233.200 for rutaecarpine, and 195.100->138.100 for caffeine.  The internal standards 
have m/z of 204.100->144.100 for caffeine-d9 and 477.100->266.200 for loperamide. The 
injection volume for caffeine metabolites was 5 µL and caffeine and rutaecarpine was 1 µL.   
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Sample analyses were determined by using a 10-point calibration curve from 3.05ng/ml 
to 20000ng/ml. Peak area ratio of parent/IS were plotted against nominal analyte concentrations 
which was fit with quadratic regression using 1/x*x weighting.  The R values were above 0.99. 
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APPENDIX B: PROTOCOL OF MOUSE STUDY  
Material and Animal 
Caffeine is purchased from Chem-Impex International Inc. Rutaecarpine is donated from 
Linnet Biopharmaceuticals.   
Dose Administration 
Animals will not be fasted. The individual test article doses will be based on body 
weights recorded on Study Day 1 of each phase. The oral doses will be administered with a 
gavage needle. The EtOH/CrEL/water and rutaecarpine formulations was prepared once on 
Study Day 1 of each phase. The caffeine formulation was prepared once on Study Day 5 of each 
phase. The EtOH/CrEL/water–based formulations will be prepared by stepwise addition of the 
vehicle components to the test article. After dosing, any remaining dose formulations will be 
stored frozen at approximately -70°C. 
Animals  
C57 Black (C57BL/6NHsd) male mice (20 - 40 g, 7 – 10 weeks) were obtained from 
Envigo RMS, Inc. C57 Black (C57BL/6NHsd) male mice study was conducted in Covance. 
Environmental controls for the animal room were set to maintain 20°C to 26°C, a relative 
humidity of 30% to 70%, a minimum of 8 air changes/hour, and a 12-hour light/12-hour dark 
cycle. The light/dark cycle may be interrupted for study-related activities. Animals will be 
acclimated for at least 3 days prior to dose administration.  
On the day of arrival, animals will be observed for mortality and signs of pain and 
distress at least once, and cage side observations may be done for general health and appearance. 
Beginning on the day after arrival, animals will be observed for signs of pain and distress at least 
twice daily (a.m. and p.m.), and cage side observations for general health and appearance will be 
performed once daily. Additional observations may be conducted and any unusual observations 
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will be recorded in the raw data. All animal protocols were applicable Covance Standard Operating 
Procedures (SOPs), and with generally recognized good laboratory practices.  
Animal Treatment  
 Certified Rodent Diet #2016C and/or #2016CM (Envigo RMS, Inc.) will be 
provided ad libitum. Water will be provided ad libitum. Water samples are routinely analyzed for 
specified microorganisms and environmental contaminants. The results are on file at Covance-
Madison. 
C57 Black (C57BL/6NHsd) male mice were randomly divided into 2 groups, as 
described in study design.  Blood (approximately 10 μL) was collected by a tail nip procedure 
into barcode-labeled capillary tubes containing K2EDTA from each animal at 
approximately 0.25, 0.5, 1, 2, and 4 hours post dose on Study Day 5 of each phase. Times will be 
based on the caffeine dose. Blood will be transferred into tubes containing 40 μL of potassium 
(K2)-EDTA in water (1.7 mg/mL).  
Blood will be vortexed and immediately placed on dry ice prior to storage at 
approximately -60°C to -80°C. Sample tubes will be labeled according to Covance SOP, 
including the Sponsor reference number and sample type (i.e., Blood/PK). All time points are 
taken within acceptable time ranges as list below: 0 - 15 minutes, within 1 minute; 16 - 30 
minutes, within 2 minutes; 31 - 45 minutes within 3 minutes; 46 - 60 minutes, within 4 minutes; 
61 minutes – 2 hours, within 5 minutes; 2 hours, 1minutes – 8 hours within 10 minutes.  
 Liver tissue was collected at the time of euthanasia. Liver was excised, rinsed with saline 
and blotted dry. Then placed into tared barcode-labeled 50 ml plastic Falcon tubes and placed on 
wet ice prior to storage at approximately -80°C.  
121 
 
APPENDIX C: METABOLITES AND CAFFEINE INDIVIDUAL DATA OF RAT STUDY 
Caffeine Metabolites Concentration Time Course 
Figure 45-47 show the plot of plasma concentration vs. time for Caffeine’s three major 
metabolites: paraxanthine, theobromine and theophylline with or without presence of βNF and 
I3C in rats. All the formation rates of these three metabolites have similar pattern.  All 
paraxanthine, theobromine and theophyline’s formation rates are faster in I3C and βNF than 
those in vehicle group from 0 to 3 hours. This is because of the inducing cyp1a2 enzyme by I3C 
and βNF. For the maximum concentration, the I3C group reached to its maximum concentration 
at about 3 h, βNF group was at 5 h, and the Veh group kept increasing. After 3 hours, the 
metabolites in I3C groups deceased faster than βNF group, this is consistent with their AUClast 
(Table 13) which obtained up to 10 hours, for instance AUClastparaxanthine,βNF is 73.3±7.2 
h*umol/L which is bigger than  AUClastparaxanthine,I3C  30.2±6.7 h*umol/L. Theobromine and 
theophylline have difference, detail can be found in table 13. Detailed metabolites level in 
individual rat are listed in Appendix.  
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Figure 43: Comparison of average plasm concentration-time profiles of paraxanthine among 
pretreatment of vehicle, bNF and I3C in rats.  
 
 
 
Figure 44: Comparison of average plasm concentration-time profiles of theobromine among 
pretreatment of vehicle, bNF and I3C in rats.  
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Figure 45: Comparison of average plasm concentration-time profiles of theophylline among 
pretreatment of vehicle, bNF and I3C in rats.  
 
 
 
Table 13: Average pharmacokinetic parameters of paraxanthine, theophylline and theobromine 
after 20 mg/kg intragastrical dose of caffeine with or without presence of βNF or I3C.  
  
Pre-
treatment  
AUClast Clast Tlast Cmax Tmax MRTlast 
 
  (h*μg/mL)  (μg/mL)  (hr)  (umol/L)  (hr)  (hr)  
Paraxanthine Veh 7.2±0.8 1.4±0.1 10.0 7.0±0.5 9.6±0.9 6.9±0.1 
 BNF 
14.2±1.4 0.6±0.3 10.0 
11.4± 
2.1 
4.2±1.1 5.2±0.3 
 I3C 
5.9±1.3 
0.03± 
0.01 
10.0 7.1±1.2 2.6±0.9 3.4±0.1 
Theophylline Veh 5.8±0.6 1.1±0.0 10.0 5.6±0.3 9.6±0.9 6.9±0.1 
 BNF 9.8±1.1 0.6±0.2 10.0 7.5±1.4 5.0±0.0 5.6±0.3 
 I3C 7.9±7.2 0.2±0.1 10.0 4.6±1.1 2.6±0.9 3.9±0.1 
Theobromine 
Veh 
5.2±0.5 1.2±0.1 10.0 6.1±0.4 
10.0± 
0.0 
7.1±0.1 
 BNF 
14.8±1.1 1.4±0.4 10.0 
10.8± 
1.2 
6.2±1.6 5.9±0.2 
 I3C 6.6±1.8 0.1±0.0 10.0 7.5±1.8 3.0±0.0 4.3±0.2 
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Table 14: Pharmacokinetic parameters of paraxanthine, theobromine and theophylline of each 
SD rat following 20 mg/kg intragastrical dose of caffeine with pretreatment of vehicle.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analyte Subject AUClast Clast Tlast Cmax Tmax MRTlast 
    (hr*umol/L)  (umol/L)  (hr)  (umol/L)  (hr)  (hr)  
Paraxanthine R001 34.6 6.88 10 6.88 10 6.85 
 R002 32.7 6.27 10 6.27 10 6.85 
 R003 43.4 7.55 10 7.55 8 6.83 
 R004 36.9 7.33 10 7.33 10 6.96 
  R005 37.5 7.1 10 7.1 10 6.86 
 Mean 37 7.03 10 7.03 9.6 6.87 
  SD 4.04 0.49 0 0.49 0.894 0.0537 
Theobromine R001 25.9 5.99 10 5.99 10 7.1 
 R002 24.6 5.94 10 5.94 10 7.15 
 R003 31.3 6.88 10 6.88 10 7.12 
 R004 25.9 6.05 10 6.05 10 7.2 
  R005 26.1 5.83 10 5.83 10 7.06 
 Mean 26.7 6.14 10 6.14 10 7.13 
  SD 2.61 0.424 0 0.424 0 0.0512 
Theophylline R001 28.3 5.66 10 5.66 10 6.92 
 R002 28.7 5.46 10 5.46 10 6.89 
 R003 35 5.99 10 6.11 8 6.84 
 R004 26.8 5.35 10 5.35 10 6.99 
  R005 30.2 5.53 10 5.53 10 6.86 
 Mean 29.8 5.6 10 5.62 9.6 6.9 
  SD 3.16 0.249 0 0.294 0.894 0.058 
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Table 15: Pharmacokinetic parameters of paraxanthine, theobromine and theophylline of each 
SD rat following 20mg/kg intragastrical dose of caffeine with presence of β-naphthoflavone.  
Analyte Subject AUClast Clast Tlast Cmax Tmax MRTlast 
    (hr*umol/L)  (umol/L)  (hr)  (umol/L)  (hr)  (hr)  
Paraxanthine R101 81.1 4.96 10 11.7 5 5.59 
  R102 75.7 1.52 10 12.1 3 4.77 
  R103 70.8 1.93 10 10.7 3 5.06 
  R104 76.7 1.79 10 14.2 5 5.02 
  R105 62.2 4.45 10 8.44 5 5.43 
  Mean 73.3 2.93 10 11.4 4.2 5.17 
  SD 7.18 1.64 0 2.11 1.1 0.332 
Theobromine R101 80.9 9.38 10 11.5 5 6.21 
  R102 77.6 5.07 10 11.5 5 5.64 
  R103 76.8 6.16 10 10.7 8 5.86 
  R104 78.5 5.94 10 11.4 5 5.82 
  R105 66.6 8.49 10 8.83 8 6.1 
  Mean 76.1 7.01 10 10.8 6.2 5.93 
  SD 5.5 1.83 0 1.17 1.64 0.228 
Theophylline R101 57 4.98 10 8.38 5 6.01 
  R102 53.8 2.07 10 8.33 5 5.26 
  R103 49 2.55 10 6.49 5 5.52 
  R104 51.4 2.35 10 8.83 5 5.51 
  R105 42.2 3.93 10 5.55 5 5.85 
  Mean 50.7 3.17 10 7.52 5 5.63 
  SD 5.58 1.24 0 1.42 0 0.295 
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Table 16: Pharmacokinetic parameters of paraxanthine, theobromine and theophylline of each 
SD rat following 20mg/kg intragastrical dose of caffeine with presence of indole-3-carbinol. 
Analyte Subject AUClast Clast Tlast Cmax Tmax MRTlast 
    (hr*umol/L)  (umol/L)  (hr)  (umol/L)  (hr)  (hr)  
Paraxanthine R201 18.6 0.147 10 5.21 1 3.51 
  R202 31.3 0.224 10 6.55 3 3.41 
  R203 31.5 0.0877 10 7.77 3 3.18 
  R204 34.6 0.208 10 7.88 3 3.47 
  R205 34.9 0.0921 10 8.05 3 3.36 
  Mean 30.2 0.152 10 7.09 2.6 3.39 
  SD 6.68 0.0632 0 1.21 0.894 0.128 
Theobromine R201 27.3 0.561 10 4.48 3 4.26 
  R202 40.8 0.805 10 7.6 3 4.28 
  R203 37.3 0.322 10 8.05 3 3.93 
  R204 43.4 0.888 10 8.21 3 4.39 
  R205 21.9 0.622 10 9.05 3 4.43 
  Mean 34.2 0.64 10 7.48 3 4.26 
  SD 9.18 0.221 0 1.75 0 0.198 
Theophylline R201 14.8 0.221 10 2.68 1 4.01 
  R202 23.1 0.283 10 4.64 3 3.92 
  R203 22 0.115 10 5.06 3 3.66 
  R204 25.4 0.294 10 5.36 3 4 
  R205 25.1 0.184 10 5.46 3 3.9 
  Mean 22.1 0.22 10 4.64 2.6 3.9 
  SD 4.33 0.0735 0 1.14 0.894 0.14 
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Caffeine Metabolites Concentration Time Course 
 
Figure 46: Average concentration vs. time plot of paraxanthine, intravenous dose of caffeine 
(15mg/kg) with or without presence of CH (5mg/kg) and Rut (100 mg/kg) in SD rats. N=4.  
 
 
 
 
Figure 47: Average concentration vs. time plot of theophylline, after intravenous dose of caffeine 
(15mg/kg) with or without presence of CH (5mg/kg) and Rut (100 mg/kg) in SD rats. N=4. 
0.01
0.1
1
10
0 2 4 6 8 10
co
n
ce
n
tr
a
ti
o
n
 (
μ
g
/m
l)
Time (h) 
Paraxanthine
Caffeine (IV, 15 mg/kg)
Par-CafIV-Veh
Par-CafIV-CH
Par-CafIV-Rut
Par-CafIV-Rut+CH
0.001
0.01
0.1
1
10
0 2 4 6 8 10
co
n
ce
n
tr
a
ti
o
n
 (
μ
g
/m
l)
Time (h) 
Theophylline 
Caffeine (IV, 15 mg/kg)
Theop-CafIV-Veh
Theop-CafIV-CH
Theop-CafIV-Rut
Theop-CafIV-Rut+CH
128 
 
 
Figure 48: Average concentration vs. time plot of theobromine, after intravenous dose of caffeine 
(15mg/kg) with or without presence of CH (5mg/kg) and Rut (100 mg/kg) in SD rats. N=4. 
 
 
 
 
Figure 49: Average concentration vs. time plot of paraxanthine, after orally dose of caffeine (20 
mg/kg) with or without presence of CH (5mg/kg) and Rut (100 mg/kg) in SD rats. N=4. 
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Figure 50: Average concentration vs. time plot of theophylline, after orally dose of caffeine (20 
mg/kg) with or without presence of CH (5mg/kg) and Rut (100 mg/kg) in SD rats. N=4. 
 
 
 
Figure 51: Average concentration vs. time plot of theobromine, after orally dose of caffeine (20 
mg/kg) with or without presence of CH (5mg/kg) and Rut (100 mg/kg) in SD rats. N=4. 
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APPENDIX D. INDIVIDUAL DATA OF MOUSE STUDY 
 Table 17: Caffeine’s pharmacokinetic data of each wild type mouse following intravenously bolus 30 mg/kg caffeine with or without 
presence of (100mg/kg) rutaecarpine. 
M001-M005 are vehicle group. M101-M105 are rutaecarpine group.  
Mice 
ID 
AUClast AUCINF_obs AUC% 
Extrap_obs 
(%) 
AUCINF/D Cl_obs* Clast C0 Tmax λz MRTINF MRTlast Vssobs Vz_obs 
(h*umol/ 
L)  
(h*umol/ L)  
(h*kg*umol/ 
L/umol)  
(mL/min/ 
kg)  
(umol/ 
L)  
(umol/ 
L)  
(h)  (h)  (h)  (h)  (L/kg)  (L/kg)  
M001 393 513 23.4 3.33 5 42.6 155 0.5 1.95 2.81 1.59 0.845 0.845 
M002 346 409 15.4 2.65 6.28 30.2 113 0.5 1.44 2.28 1.59 0.861 0.785 
M003 335 393 14.7 2.55 6.53 27.9 189 0.25 1.43 2.22 1.56 0.871 0.81 
M004 326 377 13.5 2.45 6.82 23.7 167 0.25 1.49 2.1 1.47 0.858 0.876 
M005 339 360 5.84 2.33 7.14 14.2 128 0.5 1.02 1.65 1.42 0.709 0.632 
Mean 348 410 14.6 2.66 6.35 27.7 150 0.4 1.47 2.21 1.53 0.829 0.79 
SD 26.4 60.3 6.23 0.392 0.82 10.3 30.4 0.137 0.329 0.416 0.080 0.068 0.095 
M101 220 221 0.765 1.44 11.6 2.1 101 0.5 0.56 1.11 1.08 0.774 0.562 
M102 315 318 0.981 2.06 8.08 3.37 371 0.25 0.642 1.02 0.981 0.494 0.449 
M103 256 258 0.8 1.68 9.94 2.69 115 0.5 0.532 1.2 1.17 0.713 0.458 
M104 277 280 1.22 1.82 9.16 4.11 217 0.25 0.577 1.18 1.13 0.646 0.458 
M105 293 296 0.972 1.92 8.68 3.06 237 0.25 0.65 1.11 1.08 0.58 0.489 
Mean 272 275 0.948 1.78 9.49 3.07 208 0.35 0.592 1.12 1.09 0.642 0.483 
SD 36.2 36.8 0.181 0.239 1.36 0.752 109 0.137 0.052 0.069 0.0703 0.11 0.047 
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Table 18: Caffeine’s pharmacokinetic data of each wild type mouse following intragastrical 40 
mg/kg caffeine with or without presence of (100mg/kg) rutaecarpine. 
 
M001-M005 are vehicle group. M101-M105 are rutaecarpine group.  
 
 
 
 
Figure 52: Time course of caffeine plasma concentrations following 30 mg/kg caffeine 
administered intravenously of each wild type (WT) mice in the vehicle control group.   
1.00
10.00
100.00
0 2 4 6C
o
n
ce
n
tr
a
ti
o
n
 (
u
g
/m
l)
Time (h)
Caffeine IV (30mg/kg)
WT-Veh
Veh 1
Veh 2
Veh 3
Veh 4
Veh 5
Subject 
AUClast Clast Tlast Cmax Tmax MRTlast Weight  
(h*umol/L)  (umol/L)  (hr)  (umol/L)  (h)  (h)  (g) 
M001 432 73.1 4 143 1 1.9 27.70 
M002 466 62.8 4 178 1 1.9 27.40 
M003 249 37.1 4 91.7 1 1.84 25.70 
M004 193 37.1 4 79.3 1 1.86 28.50 
M005 283 45.6 4 94.2 2 1.98 27.20 
Mean 325 51.2 4 117 1.2 1.9 27.30 
SD 119 16.2 0 41.9 0.447 0.0536 0.91 
M101 82.5 1.61 4 45.9 1 1.33 26.80 
M102 188 9.22 4 90.1 2 1.81 27.60 
M103 136 7.67 4 60.8 1 1.65 26.40 
M104 167 10.2 4 81.9 1 1.53 25.40 
M105 273 13.1 4 126 1 1.61 25.60 
Mean 169 8.35 4 81 1.2 1.59 26.36 
SD 70.2 4.26 0 30.7 0.447 0.177 0.80 
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Table 19: Paraxanthine, theobromine and theophyline’s pharmacokinetic data of each wild type 
mouse following intravenously bolus (30 mg/kg) caffeine in vehicle control group.  
  
Mice ID 
AUClast Clast C0 Tmax MRTlast 
Analyte (h*umol/L)  (umol/L)  (umol/L)  (h)  (h)  
Paraxanthine M001 51 21.4 1.86 4 2.69 
  M002 48.9 20.3 1.29 4 2.66 
  M003 48.9 18.2 2.15 4 2.54 
  M004 42.1 12.9 1.76 2 2.47 
  M005 50.3 14.1 1.7 2 2.42 
  Mean 48.2 17.4 1.75 3.2 2.56 
  SD 3.54 3.74 0.313 1.1 0.118 
Theobromine M001 24.3 10.9 0.788 4 2.75 
  M002 22.3 9.71 0.561 4 2.72 
  M003 22.7 8.77 0.921 4 2.59 
  M004 18.8 6.27 0.644 2 2.53 
  M005 23.3 6.94 0.744 2 2.44 
  Mean 22.3 8.51 0.732 3.2 2.6 
  SD 2.1 1.91 0.138 1.1 0.132 
Theophylline M001 21 7.83 0.738 4 2.59 
  M002 18.7 6.99 0.605 4 2.58 
  M003 17.9 5.1 0.833 2 2.41 
  M004 12.9 3.62 0.528 2 2.47 
  M005 18.1 3.69 0.71 2 2.32 
  Mean 17.7 5.45 0.683 2.8 2.47 
  SD 2.95 1.91 0.118 1.1 0.115 
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Table 20: Paraxanthine, theobromine and theophyline’s pharmacokinetic data of each wild type 
mouse following intragastrical (40 mg/kg) caffeine in vehicle control group. 
Analyte Subject 
AUClast Clast Tlast Cmax Tmax MRTlast 
(h*umol/L)  (umol/L)  (h)  (umol/L)  (hr)  (hr)  
Paraxanthine M001 54.2 24.3 4 24.3 4 2.78 
  M002 63.8 26.3 4 26.3 4 2.7 
  M003 45.6 18.5 4 18.5 4 2.65 
  M004 37.3 14.5 4 14.5 4 2.57 
  M005 51.8 21 4 21 4 2.67 
  Mean 50.6 20.9 4 20.9 4 2.68 
  SD 9.89 4.66 0 4.66 0 0.076 
Theobromine M001 24.3 11.4 4 11.4 4 2.83 
  M002 28.1 11.5 4 11.5 4 2.71 
  M003 20.8 8.55 4 8.55 4 2.67 
  M004 16.6 7.1 4 7.1 4 2.67 
  M005 22.6 9.66 4 9.66 4 2.73 
  Mean 22.5 9.64 4 9.64 4 2.72 
  SD 4.24 1.88 0 1.88 0 0.0637 
Theophylline M001 24.3 10.5 4 10.5 4 2.77 
  M002 26.9 10.2 4 10.2 4 2.66 
  M003 15.6 5.49 4 5.61 2 2.58 
  M004 9.17 3.59 4 3.59 4 2.63 
  M005 18.9 7.33 4 7.33 4 2.67 
  Mean 19 7.42 4 7.44 3.6 2.66 
  SD 7.04 2.99 0 2.97 0.894 0.0688 
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Figure 53: Time course of caffeine plasma concentrations following 40 mg/kg caffeine 
administered intragastrically of each wild type (WT) mice in the vehicle control group.   
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Caffeine’s Major Metabolites: Paraxanthine, Theobromine, and Theophylline 
 
 
 
 
Figure 54: Comparison of average plasma concentration-time profiles of paraxanthine after 
intravenous dosed caffeine (30mg/kg) with or without presence of 100 mg/kg oral rutaecarpine 
pretreatment in WT and AHR KO mice. Each value represents the mean ± S.D. (n = 5 for WT, 
n=4 for WT). 
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Figure 55: Comparison of average plasma concentration-time profiles of theobromine after 
intravenous dosed caffeine (30mg/kg) with or without presence of 100 mg/kg oral rutaecarpine 
pretreatment in WT and AHR KO mice. Each value represents the mean ± S.D. (n = 5 for WT, 
n=4 for WT). 
 
 
 
 
Figure 56: Comparison of average plasma concentration-time profiles of theophylline after 
intravenous dosed caffeine (30mg/kg) with or without presence of 100 mg/kg oral rutaecarpine 
pretreatment in WT and AHR KO mice. Each value represents the mean ± S.D. (n = 5 for WT, 
n=4 for WT). 
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Figure 57: Comparison of average plasma concentration-time profiles of paraxanthine after 
orally dosed caffeine (40mg/kg) with or without presence of 100 mg/kg oral rutaecarpine 
pretreatment in WT and AHR KO mice. Each value represents the mean ± S.D. (n = 5 for WT, 
n=4 for WT). 
 
 
 
 
Figure 58: Comparison of average plasma concentration-time profiles of theobromine after orally 
dosed caffeine (40mg/kg) with or without presence of 100 mg/kg oral rutaecarpine pretreatment 
in WT and AHR KO mice. Each value represents the mean ± S.D. (n = 5 for WT, n=4 for WT). 
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Figure 59: Comparison of average plasma concentration-time profiles of theophylline after orally 
dosed caffeine (40mg/kg) with or without presence of 100 mg/kg oral rutaecarpine pretreatment 
in WT and AHR KO mice. Each value represents the mean ± S.D. (n = 5 for WT, n=4 for WT). 
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Table 21: Paraxanthine, theobromine and theophyline’s pharmacokinetic data of individual wild 
type mouse following intravenously bolus (30mg/kg) caffeine with pretreatment of (100 mg/kg) 
rutaecarpine. 
  Mice 
ID 
AUClast Clast C0 Tmax MRTlast 
Analyte (h*umol/L)  (umol/L)  (umol/L)  (h)  (h)  
Paraxanthine M101 62.8 9.77 3.86 2 2.12 
 M102 62 13.3 3.59 2 2.24 
 M103 68.8 13.3 3.4 2 2.23 
 M104 59.7 13.8 3.27 2 2.32 
 M105 68.5 12.5 5.77 2 2.21 
 Mean 64.4 12.5 3.98 2 2.22 
 SD 4.05 1.61 1.03 0 0.0704 
Theobromine M101 27.5 5.33 1.34 2 2.23 
 M102 26.7 6.61 1.22 2 2.32 
 M103 33.2 7.83 1.24 2 2.34 
 M104 25.7 6.77 1.14 2 2.4 
 M105 29.3 5.99 1.9 2 2.29 
 Mean 28.5 6.51 1.37 2 2.32 
 SD 2.94 0.932 0.307 0 0.0631 
Theophylline M101 7.52 0.226 0.833 2 1.73 
 M102 7.2 0.294 0.71 2 1.81 
 M103 8.97 0.395 0.755 2 1.82 
 M104 8.75 0.488 0.71 2 1.94 
 M105 8.38 0.285 1.14 2 1.77 
 Mean 8.17 0.338 0.83 2 1.82 
 SD 0.771 0.104 0.182 0 0.0798 
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Table 22: Paraxanthine, theobromine and theophyline’s pharmacokinetic data of individual wild 
type mouse following intragastrical (40 mg/kg) caffeine with pretreatment of (100mg/kg) 
rutaecarpine. 
Analyte Subject 
AUClast Clast Tlast Cmax Tmax MRTlast 
(h*umol/L)  (umol/L)  (h)  (umol/L)  (h)  (h)  
Paraxanthine M101 44 9.44 4 15.9 2 2.22 
  M102 78 21.1 4 30.4 2 2.44 
  M103 55.2 15.7 4 19.4 2 2.39 
  M104 68 17.6 4 25.3 2 2.37 
  M105 78.5 23.2 4 29.3 2 2.47 
  Mean 64.8 17.4 4 24.1 2 2.38 
  SD 15 5.33 0 6.26 0 0.0973 
Theobromine M101 18.2 4.37 4 6.72 2 2.31 
  M102 32.2 9.49 4 12.2 2 2.49 
  M103 24.5 7.77 4 8.44 2 2.46 
  M104 28.5 8.05 4 10.5 2 2.43 
  M105 33.9 10.8 4 12.4 2 2.52 
  Mean 27.5 8.1 4 10.1 2 2.44 
  SD 6.3 2.42 0 2.46 0 0.0822 
Theophylline M101 2.76 0.169 4 1.35 2 1.89 
  M102 7.86 0.794 4 4.75 2 2.26 
  M103 6.48 0.577 4 3.35 2 2.07 
  M104 5.08 0.456 4 2.45 2 2.02 
  M105 13 1.59 4 7.05 2 2.25 
  Mean 7.03 0.717 4 3.79 2 2.09 
  SD 3.83 0.536 0 2.21 0 0.157 
 
 
142 
 
 
Figure 60: Time course of caffeine plasma concentrations following 30 mg/kg caffeine 
administered intravenously of each AHR knock out mice in the vehicle control group.   
 
 
 
 
 
Figure 61: Time course of caffeine plasma concentrations following 30 mg/kg caffeine 
administered intravenously of each AHR knock out mice in the presence of 100 mg/kg oral 
rutaecarpine pretreatment.   
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